

Express Mailing Label No. EL813859585US

PATENT APPLICATION  
Docket No. 15070.6.2

**UNITED STATES PATENT APPLICATION**

of

**B. RON JOHNSON**

for

**ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS FOR  
TREATING PATHOGEN-INDUCED DISORDERED TISSUES**

**WORKMAN NYDEGGER**

A PROFESSIONAL CORPORATION  
ATTORNEYS AT LAW  
1000 EAGLE GATE TOWER  
60 EAST SOUTH TEMPLE  
SALT LAKE CITY, UT 84111

1                   **Related Applications**

2                   This application is a continuation-in-part of copending U.S. Application Serial No.  
3                   10/200,897, filed July 22, 2002, and entitled "Anti-Infective Composition, Methods and  
4                   Systems for Treating Disordered Tissue," which is a continuation-in-part of U.S. application  
5                   Serial No. 09/668,953, filed on September 22, 2000, now U.S. Patent No. 6,423,750, which  
6                   is a continuation-in-part of U.S. application Serial No. 09/401,076, filed September 22, 1999,  
7                   now U.S. Pat. No. 6,211,243. For purposes of disclosure, the foregoing patents and  
8                   applications are incorporated herein by reference.

9  
10                                   **BACKGROUND OF THE INVENTION**

11                   **1. The Field of the Invention**

12                   The present invention relates to the treatment of disordered tissue with anti-infective  
13                   compositions, especially antiviral, antifungal and antimicrobial compositions. More  
14                   particularly, the treatment compositions include at least one of substances such as quaternary  
15                   amine medicament compounds and organic compounds that have at least one carbon-halogen  
16                   bond. The present invention provides a novel combination of treatment compositions and  
17                   modes of applying them to treat tissue disorders, particularly epithelial tissue disorders  
18                   caused by viruses, bacteria, or fungi.

19  
20                   **2. The Relevant Technology**

21                   Tissue disorders, particularly those which impact epithelial tissue caused by all types  
22                   of Herpes, such as Herpes Simplex types I and II and Herpes Zoster (shingles), candida  
23                   albicans, chicken pox, acne, psoriasis, eczema, seborrhea, dermatitis, and pink eye are  
24                   common but often difficult to treat. Such disorders are more likely to develop in people  
25                   living with compromised sanitary conditions, the elderly, and the chronically ill. Others  
26                   susceptible to such disorders include workers in health care, agricultural workers, chemical

1 industry workers, individuals working with industrial cleaners, and painters, where chronic  
2 exposure to chemicals, pathogens, and unsanitary conditions tend to weaken and irritate  
3 epithelial tissue.

4 Herpes simplex virus (HSV-I and HSV-II) and Herpes Varicella - Zoster (chicken  
5 pox, shingles), commonly referred to as "herpes virus" or "herpes," is an infectious disease  
6 which has reached crisis proportions nationally with estimated numbers of infected people  
7 at 70%-80% of U.S. population as reported by the American Social Health Association  
8 (ASHA) and growing annually by 500,000 people or more.

9 Herpes enters the human body through minuscule breaks in the epidermal tissue  
10 usually by contact with an infected host and is marked by eruption of one or more vesicles,  
11 usually in groups, following an incubation period of approximately two to ten days.  
12 Typically the course of the infectious outbreak initiates with the prodromal stage, advancing  
13 to vesicular eruption, followed by ulceration, coalescing, resolution, and the latency period.  
14 The outbreak can last for several weeks and on average lasts one to three weeks. In some  
15 immune compromised individuals, the outbreak can last for months. The vesicles can appear  
16 anywhere on epithelial tissues including the skin or mucosa, typically appearing on the lips  
17 as cold sores, glands, oral mucosa, conjunctiva and cornea, and genitalia, anal mucosa and  
18 peri-anal tissue as herpes genitalis.

19 Herpes symptoms include inguinal swelling, pain, fever, malaise, headaches, muscle  
20 aches, and swollen glands. Some individuals with oral herpes that impacts the trigeminal  
21 nerve have excruciating facial pain, difficulty swallowing, eating and facial swelling.  
22 Individuals with the herpes that impacts the sacral nerve have pain in the genital area, upper  
23 leg pain, swelling, and on occasion great difficulty walking.

24 Herpes simplex virus (HSV) infection is recurring, residing in the nerve ganglia,  
25 then recurring due to some, as yet unknown, stimulus. Recurrent herpetic infections can be

precipitated by almost anything, including exposure to sunlight, nutritional deficiencies, stress, menstruation, immunosuppression, certain foods, drugs, febrile illness, etc.

Herpes infections pose very serious health threats, often causing blindness, increased cancer risk of the cervix, aseptic meningitis and encephalitis, neonatal deaths, viremia, the spread of the human immunodeficiency virus (HIV), etc. The devastating effects of this disease go well beyond the medical scope of human suffering; HSV is responsible for serious psychological and emotional distress as well as substantial economic loss.

Various treatments for herpes have been proposed and have included topical application of such agents as povidone-iodine, idoxuridine, trifluorothymidine, or acyclovir and its analogs. Such treatments have met with varying degrees of success. Most prior treatments have proven disappointing. Acyclovir and similar analogs, acyclic nucleosides, are taken orally for systemic treatment of HSV or they are applied topically. Acyclovir is somewhat effective in inhibiting the activity of several herpes viruses. However, acyclovir is only successful in interrupting the replication of the virus and is used to treat infectious outbreak systemically. Denavir is the topical version of an acyclovir analog. Nothing to date has proven really effective as a topical treatment. Strains resistant to acyclovir and acyclovir analogs have been reported. Individuals with Auto Immune Deficiency Syndrome (AIDS) are seriously immune-compromised and can suffer especially debilitating outbreaks of HSV. Additionally, AIDS individuals may carry acyclovir resistant strains of HSV, which can make acyclovir ineffective for these individuals. It would therefore be an improvement in the art to develop a safe and successful medical treatment to overcome the very serious problems caused by the herpes virus.

Biologically active antiviral and microbial compositions have been met with marginal success when administered topically for tissue disorders. Such compositions have been applied as gels, creams, lotions, oils, ointments, pastes, tinctures, emulsions, and colloidal suspensions. Most of the compositions are oil-based to ensure that the composition

1 has sufficient viscosity and/or tackiness to remain on the surface of the skin. In fact, such  
2 compositions are generally absorbed into clothing more than into the skin due to a relatively  
3 slow epidermal penetration rate. Even when sufficient time is allowed for the compositions  
4 to penetrate, they are often not sufficiently effective in treating the disordered tissue.

5 Many efforts have been undertaken to remedy the inadequate results of topically  
6 administered compositions having antiviral and antimicrobial qualities. The therapeutic  
7 effects of such compositions depend upon the specific active agent and the method of  
8 application. Many compositions of the prior art contain ingredients that may provide  
9 symptomatic relief of pain and itching, but are not claimed to be effective against Herpes  
10 infection except the drugs based on acyclovir technology, which are purported to have some  
11 topical efficacy. Additionally, most compositions intended to treat such disorders do not  
12 effectively treat the discomfort and the disease symptoms, let alone cure the disorder or put  
13 it into a significant remission.

14 Examples of conventional application methods and compositions are provided in  
15 WO 98/42188 and in WO 98/11778 by Squires, both of which are hereby incorporated by  
16 reference. In WO 98/42188 at page 9, lines 12-18 and in WO 98/11778 at page 5, lines 22-  
17 30, it is stated that the composition is applied by "spraying, dabbing, dusting, swabbing,  
18 sponging, brushing, pouring, dispensing, covering or heavily coating." The stated objective  
19 of these techniques for applying the composition is to insure that the composition remains  
20 on the infected area. Like other conventional treatment compositions, the composition has  
21 a viscosity and/or tackiness which enables it to remain on the surface of the infected area.  
22 A portion of such compositions may eventually penetrate beyond the surface of the  
23 disordered tissue such as the outer surface of skin or a lip; however, the viscosity of the  
24 composition, combined with the application technique, prevents such compositions from  
25 achieving effective penetration.

1 Another example of conventional application methods and compositions is provided  
2 in U.S. Patent No. 5,753,270 to Beauchamp et al., which is also incorporated by reference.  
3 U.S. Patent No. 5,732,270 discloses a composition which includes: (a) an antiseptic and/or  
4 anesthetic compound which is (i) a terpene, such as menthol or eucalyptol or (ii) a phenolic  
5 compound, such as thymol; (b) a quaternary ammonium antiseptic compound, such as  
6 benzethonium chloride; and (c) an antiseptic compound containing iodine, salts thereof  
7 and/or complexes thereof dissolved in an organic skin penetrating solvent, such as a mixture  
8 of water and acetone. The methodology is described in the examples provided at columns  
9 5-7 as involving the liberal application of the composition to the afflicted area in a sequence  
10 such as 3 to 4 applications over a one minute period which is then repeated every 3 minutes  
11 over a 10 minute period. The entire procedure is then repeated after approximately 1/2 to 1  
12 hour for 2 to 3 hours or until activity is stopped in healing is evident. The use of a cotton  
13 swab is mentioned at column 6, lines 10-11 for applying the composition.

14 Although it is mentioned in U.S. Patent No. 5,753,270 at column 3, lines 44-49 that  
15 the formulations may be prepared as a gel, cream, a lotion, an ointment, or a paste, the  
16 preferred embodiment appears to be a solution having an aqueous solvent system. It is noted  
17 at column 3, lines 6-9 that although use of water and acetone as a solvent is preferred, such  
18 a solvent is not considered essential to the overall synergistic action of the formulation. In  
19 any event, the formulation appears not to rely on either its viscosity or tackiness to ensure  
20 that the formation is maintained on the surface of the afflicted area as do most conventional  
21 compositions. Rather the methodology involves the very frequent reapplication of the  
22 formulation to the afflicted area. Some of the formulation may be absorbed into the skin;  
23 however, a significant portion is likely rapidly evaporated due to the high content of water  
24 and acetone.

25 The active agents disclosed in U.S. Patent No. 5,753,270 that are discussed above  
26 include at least one compound which is an antiseptic and/or an anesthetic. The primary

1 examples of such compounds--menthol, eucalyptol, and thymol--are either obtained from  
2 natural sources, such as naturally occurring oils, or are derived from such oils. Eucalyptol  
3 is described as being an essential oil and a terpene ether. Thymol is derived from thyme oil  
4 or other oils. Menthol is obtained from peppermint oil or other oils. Other suitable  
5 compounds are also recited in the claims as including eugenol, camphor, hexetidine, or  
6 anethol. While the basis for inclusion of hexetidine in this grouping is not clear, the other  
7 chemicals are also obtained from natural sources or are derived therefrom. Eugenol is  
8 obtained by extraction of clove oil and then chemical modification. Camphor is a ketone  
9 which occurs naturally in the wood of the camphor tree. Anethol is derived from anise or  
10 fennel oils. While these compounds are useful, particularly as antifungal agents, it is  
11 doubtful that they assist in penetrating the afflicted tissue and may in fact retard penetration  
12 or enhance the skin's natural resistance to penetration. The FDA does not consider these  
13 compounds as useful in the treatment of herpes, rather they are used for their softening  
14 effects.

15 In conclusion, significant medical research in this field of endeavor has been focused  
16 on developing compositions used for treating affected tissues and yet compositions which  
17 provide rapid relief to these ailments are still needed. It would therefore be an improvement  
18 in the art to provide compositions, systems and methods for treating tissue disorders (such  
19 as epithelial tissue disorders) that overcome the problems of the prior art.

20 Such compositions, methods and systems of application are taught and claimed  
21 herein.

# SUMMARY OF THE INVENTION

The present invention relates to the treatment of disordered tissues caused by pathogens (*e.g.*, viruses, bacteria or fungi). An applicator may be used to apply a treatment composition comprising an anti-infective active agent in a carrier. The method may include vigorously agitating the disordered tissue treatment site with the applicator under conditions that enable the anti-infective active agent to rapidly penetrate the disordered tissue.

The present invention relates to the treatment of tissue disorders such as infections, particularly herpes related cold sores or other herpes disordered tissue. Throughout this disclosure, the terms "disordered tissue" or "afflicted tissue" are understood to represent all tissue which has been affected by disorders such as all herpes, including, but not restricted to, cold sores, genital herpes and shingles, and chicken pox, forms of Zoraster, also disorders such as cow pox-vaccinia virus, smallpox and anthrax, candida albicans, acne, psoriasis, eczema, seborrhea, dermatitis, pink eye, and other predominantly viral disorders. Thus, various viral, microbial and fungal infections are examples of disordered tissues. Additionally, disordered tissue includes tissue which has been infected by toxins, such as snake or spider venom, as results from snake and spider bites, *e.g.*, venom infections from Brown Recluse spiders and Black Widow spiders.

It has been found that the therapeutic irritation of disordered tissue with a preferred treatment composition and the optional use of an applicator, stimulates rapid immunological attack and makes the composition and therapeutic irritation synergistically more effective. After the therapeutic irritation of the disordered tissue through vigorous rubbing and/or pressure, the treatment composition penetrates into the disordered tissue to enable the anti-infective active agent or agents to become chemically active much more deeply within the disordered tissue as compared to conventional application techniques.

In addition to the anti-infective active agent or agents, the composition also includes a carrier such as an alcohol. Oil and fatty carrier substances are preferably not added to the



1 composition to the extent they inhibit penetration of the treatment composition into the skin.  
2 Although various compositions have been applied to disordered tissue, the inventive methods  
3 and systems of vigorous irritation of the disordered tissue in connection with a preferred  
4 composition has extraordinary therapeutic effects. Consequently, the inventive compositions  
5 as well as the methods of application with vigorous irritation of disordered tissue provide  
6 effective methods of treatment.

7 The inventive systems utilize an applicator to deliver the treatment composition and  
8 most of the applicators can also be utilized to vigorously irritate disordered tissue to convey  
9 the inventive composition into the disordered tissue. The applicators allow the patient or a  
10 health professional to vigorously irritate the disordered tissue without cross-contamination  
11 from a dirty finger or the like. A finger may be used, of course, but it lacks the advantages  
12 of a sterile applicator, the absorbability of an applicator tip and the ability to irritate the skin  
13 surface in the desired manner. The applicator has the added advantage of directing focused  
14 pressure into the disordered tissue while the active compounds are expressed from the  
15 applicator into the disordered tissue. The combined effect of vigorous irritation of the  
16 disordered tissue and the administration of the inventive treatment compositions has the  
17 remarkable result of surprising therapeutic effects. Note that oils on the finger may react  
18 with the active agent and lessen its impact in the disordered tissue. For this same reason,  
19 moisturizing lotions that contain substantial quantities of fats or oils are preferably not  
20 applied to the treatment area after application of the treatment composition.

21 It is therefore an object of the present invention to provide a method for treating  
22 disordered tissues, such as disordered portions of skin and mucous membranes. It is an  
23 object of one embodiment of the present invention to provide a system for the treatment of  
24 epithelial tissue disorders that includes a preferred biologically anti-infective active  
25 composition and an applicator in connection with delivering the treatment composition and  
26 also preferably vigorously irritating the disorder site.

1           These and other objects and features of the present invention will become more fully  
2           apparent from the following description and appended claims, or may be learned by the  
3           practice of the invention as set forth hereinafter.

1                                    **BRIEF DESCRIPTION OF THE DRAWINGS**

2            In order that the manner in which the above-recited and other advantages and objects  
3 of the invention are obtained, a more particular description of the invention briefly described  
4 above will be rendered by reference to specific embodiments thereof which are illustrated  
5 in the appended drawings. Understanding that these drawings depict only typical  
6 embodiments of the invention and are not therefore to be considered to be limiting of its  
7 scope, the invention will be described and explained with additional specificity and detail  
8 through the use of the accompanying drawings in which:

9            Figure 1 is a vertical cross-section of the epidermis and the papillae of the dermis;

10           Figure 2A is an exploded perspective view of a preferred applicator that contains the  
11 treatment composition;

12           Figure 2B is a perspective view of the preferred applicator depicted in Figure 2A as  
13 it appears assembled prior to use;

14           Figure 2C is a perspective view of the preferred applicator depicted in Figure 2B  
15 after the glass reservoir is crushed and the treatment composition is allowed to permeate the  
16 agitation pad;

17           Figure 2D is a perspective view of an individual applying the treatment composition  
18 according to the present invention;

19           Figure 2E is a detail taken along the section line 5-5 that depicts a close-up view of  
20 the inventive method;

21           Figure 2F shows a sheet of material before it is folded or collapsed to form an  
22 application pad;

23           Figure 3 is an elevational cross section view of an applicator that has a finger loop  
24 for vigorous topical irritation of the treatment site;

25           Figure 4 is an elevational side view of an alternative applicator used in the present  
26 invention;

1           Figure 5 is an elevational side view of an alternative applicator that is fixed to a digit  
2 for vigorous topical irritation of the treatment site;

3           Figure 6 is a cross-sectional plan view of an alternative applicator that is placed over  
4 a digit and that is contained in a pre-wetted state before use;

5           Figure 7 is a perspective view with a partial break-away view of an alternative  
6 applicator that is used to apply the treatment composition to large surface areas of the body;

7           Figure 8 is a perspective view of the alternative applicator in Figure 7 being used to  
8 apply the treatment composition to sores from shingles on the chest area;

9           Figure 9 is a perspective view of a towelette being used to apply the treatment  
10 composition to a cold sore;

11           Figure 10 is a perspective view of a towelette being used to apply the treatment  
12 composition to a sore on male genitalia; and

13           Figure 11 is a perspective view of a towelette being used to apply the treatment  
14 composition to sores from shingles on the chest area.

1                   **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**

2                   The present invention relates to the treatment of disordered tissue with compositions  
3                   that are at least one of antiviral, antimicrobial, antifungal, and antivenomous. The  
4                   compositions are rapidly absorbed into the disordered tissue. The efficacy of the  
5                   compositions in penetrating the disordered tissue and initiating the restoration of the  
6                   disordered tissue is enhanced by vigorously irritating the disordered tissue site. The  
7                   disordered tissue is preferably vigorously agitated with an applicator. This is remarkably  
8                   efficacious in causing the compositions to penetrate into disordered tissue and/or to stimulate  
9                   the immune responses. Whether the anti-infective compositions are rubbed onto the  
10                  disordered tissue or delivered with vigorous agitation of the disordered tissue, the results are  
11                  surprisingly advantageous in the treatment of epithelial tissue disorders.

12                 Hereinbelow is a discussion of what is meant by vigorous irritation of disordered  
13                 tissue, followed by a detailed description of the treatment composition. The description of  
14                 the treatment composition is followed by a detailed description of several embodiments of  
15                 applicators. FIGS. 2A-2F depict a preferred applicator. Other embodiments of applicators  
16                 are shown in FIGS. 3-8. FIGS. 9-11 depict towelettes being used. Figure 1 depicts a cross-  
17                 sectional view of skin.

18                 The phrase "vigorous agitation" means that the skin is irritated in a manner that  
19                 allows the inventive compositions to penetrate below the surface of the skin, preferably to  
20                 a nerve ending in the case where the pathogenic agent and/or toxin is located in the nerve  
21                 region (*e.g.*, HSV). As described in more detail hereinbelow, such vigorous agitation is  
22                 achieved through either applying an appropriate amount of pressure for an adequate period  
23                 of time and/or appropriate rubbing for an adequate period of time. Vigorous agitation is  
24                 preferably a combination of both adequate pressure and rubbing.

25                 A suggested theory for the effectiveness which results from vigorously agitating the  
26                 disordered tissue is set forth below. However, it should be understood that the objective in

1 vigorously agitating the disordered tissue includes altering the tissue to better enable the  
2 treatment composition to physically move through the layers of the disordered tissue by  
3 moving the cells and fluids in the disordered tissue. Also, another objective of vigorous  
4 agitation is to stimulate the immune responses.

5 Vigorous agitation achieved through applying appropriate pressure may be  
6 understood to be an amount of pressure such that, where tissue overlies bone, the tissue is  
7 depressed to be firmly against the bone. Similarly, if the disordered portion of the tissue is  
8 adjacent to teeth or gums such as the skin around the mouth, then the disordered tissue is  
9 sufficiently compressed due to the pressure that the pressure is felt on the opposing surfaces  
10 within the mouth. Additionally, if disordered tissue located around a patient's lip is also  
11 opposite the patient's gums then pressure applied to the disordered tissue would also be felt  
12 at the portion of the patient's gums opposite the disordered tissue through the lip or cheek.

13 Vigorous agitation achieved through rubbing involves repeated movement of the  
14 applicator in a frictional manner with the disordered tissue. For example, the applicator may  
15 be moved in a steady back and forth motion on the disordered tissue or rotated as the  
16 treatment composition is applied or after delivery of the composition. As described in  
17 greater detail in reference to the applicator, the applicator is preferably configured to provide  
18 a relatively uniform abrasive action. The oscillation rate of the back and forth motion  
19 depends on several factors such as the amount of pressure being simultaneously applied and  
20 the condition of the disordered tissue. So in some instances the oscillation rate may be only  
21 1 stroke every few seconds while in other circumstances the oscillation rate may range from  
22 about 1 strokes per second to about 10 strokes per second. More typically, however, the  
23 oscillation rate is in a range from about 2 strokes per second to about 6 strokes per second  
24 and is most typically in a range from about 3 strokes per second to about 4 strokes per  
25 second. Note that the portion of the applicator used to rub the disordered tissue preferably  
26 has a size in a range from about 50% to about 200% the size of the disordered tissue

1 treatment site. For example, it has been found that a contact surface that is about 8 mm in  
2 diameter is useful for agitating most cold sore treatment sites.

3 The length of time that vigorous agitation of this type may be sustained upon a  
4 disordered tissue treatment site may vary according to the individual, the size of the  
5 applicator surface in relation to the size of the disordered tissue to be agitated, the amount  
6 of pressure applied as defined above and the oscillation rate of the rubbing. As the length  
7 of time increases in which the applicator delivery surface is maintained in contact with the  
8 disordered tissue, the required pressure decreases for achieving the desired penetration of the  
9 treatment composition into the disordered tissue. Typically, the vigorous agitation is  
10 maintained for at least 1 second and is more typically maintained for a few seconds.  
11 However, the period of time may range from about 3 seconds to about 1 minute depending  
12 on the condition of the disordered tissue, the amount of pressure being applied and/or the  
13 movement of the applicator. Vigorous agitation is most typically maintained for a period of  
14 time in a range from about 5 seconds to about 15 seconds.

15 The intensity of the vigorous agitation is adjusted depending on the thickness of the  
16 skin. For example, the tissue on a lip that must be penetrated is much thinner than that of the  
17 skin on the arms, legs, and chest. The thickness is even greater for the skin on the palms of  
18 hands and feet and is still greater for other body parts such as backs. So it may be necessary  
19 to vigorously agitate the disordered tissue with greater intensity when treating sores on a  
20 patient's chest or back caused by shingles then the vigorous agitation is required to treat a  
21 cold sore on one's lip.

22 It is counterintuitive to vigorously agitate disordered tissue such as a cold sore as the  
23 disordered tissue already hurts so one inherently desires to avoid even contacting such  
24 sensitive disordered tissue. However, patients are likely to be more tolerant of any pain  
25 which may result from vigorous agitation when bolstered by knowledge that vigorous

1 agitation significantly enhances the ability of the treatment compositions disclosed herein to  
2 effectively penetrate and cure disordered tissue.

3 Vigorous agitation need not necessarily be painful, although vigorous agitation may  
4 also be understood to mean that discomfort is felt by the patient beyond nominal dabbing of  
5 the disordered tissue as with other treatments that call for gentle application to the disordered  
6 tissue. Before a cold sore has erupted, and is in the prodromal stage or vesicular stage such  
7 that at most there is merely a vistule, it may not be painful to vigorously agitate the  
8 disordered tissue. However, when vigorously agitating disordered tissue which is in an  
9 erupted stage, the agitation may be sufficient to cause sharp pain and bleeding.

10 Obviously however disordered tissue such as cold sores cannot always be vigorously  
11 agitated. As indicated above, when a cold sore is in the prodormal stage it can be vigorously  
12 agitated without significant sensitivity. However, when the cold sore has become an open  
13 sore less pressure may be utilized so as to minimize the potential for causing pain. Also, if  
14 the cold sore has coalesced then it is best not to vigorously agitate the treatment site as such  
15 action is likely to disturb the coalesced tissue, scab, etc. Also, when treating sensitive areas  
16 such as inside the mouth, mucous coated tissues, the eyes, genitalia, etc., the treatment  
17 composition should be applied without vigorous agitation.

18 As indicated above, the vigorous agitation can also be defined by contrasting it with  
19 nominal dabbing of the disordered tissue which involves the mere application of a treatment  
20 composition. The same is likewise true for other application techniques such as swabbing,  
21 sponging, and brushing merely to ensure that a treatment composition is applied or delivered.  
22 Dabbing and other application techniques do not involve pressing hard enough such that the  
23 disordered tissue is compressed against a bone or such that pressure is felt as a surface in the  
24 mouth opposite the disordered tissue is pressed against teeth or gums.

25 Despite a patient's desire to enable disordered tissue to return to normal, some  
26 patients are also likely to adjust the amount of pressure applied or the rate of rubbing in order



1 to minimize pain. However, as indicated above, it is not necessary for a patient to feel pain  
2 in order for the treatment composition to be delivered with vigorous agitation. The objective  
3 is to move the tissue somehow either through compressing the tissue through the application  
4 of an appropriate amount of pressure as discussed above for an adequate period of time  
5 and/or by rubbing the tissue in manner such that tissue is moved around for an adequate  
6 period of time for the treatment composition to penetrate such that it does not remain on the  
7 surface.

8 The treatment composition is preferably absorbed into the disordered tissue to such  
9 an extent that within several minutes after application the composition can no longer be seen.  
10 This is absorption or penetration rate is achieved either with or without vigorous agitation.  
11 More preferably, the composition is not visibly detectable within 2 minutes after being  
12 applied and is most preferably not visibly detectable within 1 minute after being applied.  
13 Note that the content of the composition has different formulations; however, in the preferred  
14 embodiment there is no significant residue remaining after the composition has been applied  
15 and absorbed that is visibly detectable.

16 As indicated above, the treatment composition preferably penetrates through the skin  
17 to a nerve ending or causes a penetration sensation at the nerve ending. The pathway for this  
18 penetration is discussed in greater detail below with reference to Figure 1. After the  
19 composition is delivered with simultaneous agitation, the penetration or the penetration  
20 sensation preferably occurs within about one minute. The penetration or penetration  
21 sensation to a nerve ending is more preferably achieved in about 30 seconds, and most  
22 preferably in less than about 10 seconds. In more serious cases when the disordered tissue  
23 represents an extensive problem and/or involves a life threatening pathogen (*e.g.*, smallpox  
24 or anthrax), several treatments may be used instead of a single, primary treatment. Note that  
25 when several treatments are used instead of a single, primary treatment, it is preferable to use  
26 a clean and sterile applicator for each repeated treatment.

1           Figure 1 is a vertical cross-section of the epidermis and the papillae of the dermis.  
2           Figure 1 illustrates the stratum corneum 28 disposed upon the fatty layer or stratum lucidum  
3           30. The stratum lucidum is disposed over the stratum granulosum 32. Below the stratum  
4           granulosum 32 is the stratum spinosum 34. Typically, the stratum spinosum 34 has a lipid  
5           film disposed around each individual cell. Below the stratum spinosum 34 is the stratum  
6           basale 38 that overlies vascularized tissue. Within the vascularized tissue the nervous papilla  
7           of the corium 36 is located along with blood vessels and nerves 40. Figure 1 shows the  
8           treatment composition being delivered to the stratum corneum 28 in order to allow treatment  
9           composition 22 to penetrate therethrough. The treatment composition is shown being  
10          delivered from an impregnated agitation pad 12 accompanied by vigorously rubbing.

11          The arrows illustrate directions of agitation movement by way of non-limiting  
12          example. Note, however, that Figure 1 does not depict the application of pressure as the  
13          objective in Figure 1 is to show the particular layers involved in their natural positions and  
14          once pressure is applied the layers are moved from their natural positions. Although the  
15          inventor does not wish to be bound to a single theory, it is postulated that treatment  
16          composition 22 may move through the stratum corneum 28 without significant rupture  
17          thereof due to the vigorous agitation by impregnated agitation pad 12. Treatment  
18          composition 22 can penetrate to the nervous papilla of the corium 36 by the combination of  
19          vigorous agitation and the penetrating nature of the carrier. Preferably, vigorous agitation  
20          and the combination of the penetrating quality of the carrier are sufficient conditions to cause  
21          the anti-infective active agent to penetrate the disordered tissue to a nerve ending such as the  
22          nervous papilla of the corium 36.

23          Note that the application of pressure further increases the ability of the treatment  
24          composition to penetrate as the pressure may flatten or compress the layers and may assist  
25          in forcing the treatment composition downward. In any event, under the inventive

1 conditions, penetration to the nerve ending is rapidly accomplished, preferably in several  
2 seconds.


3 While the treatment composition 22 rapidly penetrates to the nerve endings, it is also  
4 postulated that the treatment composition resides in reservoir amounts within the stratum  
5 spinosum 34 and may continue to diffuse across the stratum basale 38 to the nerve endings  
6 over an extended period of time. Vigorous agitation may assist in displacing fluid held  
7 within the stratum spinosum which is then replaced with the treatment composition. When  
8 the stratum spinosum 34 is filled with the treatment composition then the treatment  
9 composition is available as a bath that continues to provide protection as it slowly diffuses.  
10 On this basis, it is preferred to deliver a large quantity of the treatment composition on the  
11 disordered tissue such that the stratum spinosum 34 is saturated in the region of the cold sore  
12 or other disordered tissue for a period that enables the treatment composition to achieve its  
13 purpose before it diffuses into the body. For example, the volume applied to a typical cold  
14 sore may be in range from about 0.2 ml to about 1 ml, preferably in range from about 0.4 ml  
15 to about 0.8 ml and is most preferably about 0.6 ml. Low amounts of volume, such as about  
16 0.2 ml, work for a single cold sore especially if the applicator does not retain a significant  
17 portion of the volume however the volume is preferably greater. In order for all of the  
18 volume to be delivered, half of the total volume in the applicator may be delivered and then  
19 the remainder may be delivered. Delivery of such large volumes is discussed below in  
20 reference to the applicators used to deliver the treatment composition.

21 The treatment compositions include at least a biologically active agent and a carrier.  
22 The biologically active agent is selected so as to be effective in treating tissue disorders  
23 caused by pathogens (*e.g.*, viruses, fungi or bacteria) or toxins (*e.g.*, snake or spider venom),  
24 and the carrier is selected to optimally enable the treatment composition to penetrate into the  
25 disordered tissue, including through the cell walls of infected and/or infectious cells. The  
26 biologically active agents suitable for use in the treatment compositions are set forth

hereinbelow and the carriers are described thereafter. Other optional components are also described.

The biologically active agents or anti-infective agents included in the anti-infective treatment compositions are preferably anti-infective quaternary ammonium halides and organic compounds that contain at least one carbon-halogen bond. These anti-infective compounds are referred to herein collectively as organohalides, even though some of the anti-infective compounds of this invention do not contain a carbon-halogen bond. Biologically active agents included in anti-infective treatment compositions according to this invention comprise anti-viral organohalides. Benzalkonium chloride is a preferred organohalide. However, other organohalides or quaternary ammonium halide compounds may be used as the active agents in the compositions. Other active agents that are organohalides may include organo-bromides and organo-iodides. Preferably, the organohalides have an alkyl group attached thereto such as a simple  $C_nH_{2n+1}$  chain, where n is in a range from 1 to about 50.

The generic chemical structure of benzalkonium chloride is shown below:



wherein  $R = C_8H_{17}$  to  $C_{18}H_{37}$ . As shown, benzalkonium chloride includes a benzene ring and a nitrogen constituent (*i.e.*, a quaternary ammonium group) near the ring. A carbon atom is disposed between the nitrogen constituent and the benzene ring. Two methyl groups and an R group of varying size extend from the nitrogen atom. Suitable benzalkonium chloride may be obtained from many suppliers for example, Spectrum of Gardena, California; Stepan of

1 Northfield, Illinois; Sanofit Pharmaceuticals, Inc. of New York, NY and Mason Chemical  
2 of Arlington Heights, Illinois.

3 Benzalkonium chloride according to the present invention includes compounds in  
4 which the alkyl group chain length is within a wide range. A preferred embodiment involves  
5 a mixture of compounds with an alkyl chain length distribution that is about 40% C<sub>12</sub>, about  
6 50% C<sub>14</sub>, and about 10% C<sub>10</sub> (CAS Reg. No. 68424-85-1). Examples of such products  
7 include, but are not limited to, Maquat MC-1412-50%, Mason Chemical Company, 50%  
8 activity; Maquat MC-1412-80%, Mason Chemical Company, 80% activity; and BTC-835,  
9 Stepan Company, 50% activity. While the foregoing examples satisfy the US  
10 Pharmacopoeia requirements for alkyl chain distribution, other alkyl chain distributions are  
11 effective against the target lipid coated viruses and other target pathogens. These  
12 embodiments are also contemplated within the scope of this invention and they are used in  
13 other embodiments of the same. These ranges include about 1%-99% C<sub>12</sub>, about 1%-99%  
14 C<sub>14</sub>, and about 1%-99% C<sub>16</sub>. Each manufacturer publishes methods to analyze the supplied  
15 bulk substance. Notwithstanding the fact that benzalkonium chloride often refers to  
16 mixtures of compounds of varying alkyl chain length, it should be understood that it is within  
17 the scope of the invention to utilize a singular benzalkonium chloride compound comprising  
18 only one alkyl chain of a particular length.

19 These anti-infective agents, particularly benzalkonium chloride, are highly effective  
20 in killing pathogens (*e.g.*, viruses, bacteria or fungi) or otherwise limiting the source of  
21 infections and other complications related to disordered tissue. Also, these anti-infective  
22 agents can destroy or eliminate toxins caused by pathogens such as viruses, bacteria or fungi.  
23 Rapidly eliminating toxins and their sources results in prompt pain relief.

24 While the active agents broadly include organohalides, most suitable organohalides  
25 are organochlorides. Benzalkonium bromide and benzalkonium iodide are examples of  
26 suitable organohalides in the context of this invention which are not organochlorides.

1 Benzalkonium bromide has the structure of benzalkonium chloride with the difference being  
2 that the chlorine is substituted with a bromine constituent. Analogous considerations apply  
3 to benzalkonium iodide. Another example of a suitable organohalide which is not an  
4 organochloride is cetyl trimethylammonium bromide.

5 Examples of other organochlorides which have anti-infective properties and are  
6 suitable for use as the anti-infective organochloride in the treatment composition include  
7 benzethonium chloride, methyl benzethonium chloride, cetyl pyridinium chloride,  
8 chloroxylenol, hexachlorophene, triclosan, and chlorhexidine. Note that some of the above  
9 organochlorides are not suitable for all purposes. For example, benzethonium chloride  
10 should not be used in a manner which would enable it to be ingested in a toxic quantity.  
11 Similarly, the concentration of benzalkonium chloride must not be excessively high.

12 Additional examples of other organochlorides which may be suitable, more  
13 particularly quaternary ammonium chlorides having an alkyl with 6-18 carbons, include:  
14 alkylbenzyltrimethylammonium chloride, alkyltrimethyl/ethylbenzylammonium  
15 chloride, n-alkyltrimethylbenzylammonium chloride,  
16 diisobutylphenoxyethoxyethyltrimethylbenzylammonium chloride, n-(C<sub>12</sub>C<sub>14</sub>C<sub>16</sub>) alkyl  
17 trimethylbenzylammonium chloride, didecyltrimethylammonium chloride,  
18 dioctyltrimethylammonium chloride, dialkyltrimethylammonium chloride,  
19 dialkylmethylbenzylammonium chloride, octyldecyltrimethylammonium chloride,  
20 lauryltrimethylbenzylammonium chloride, o-benzyl-p-chlorophenol,  
21 diderlyltrimethylammonium chloride, dioctyltrimethylammonium chloride, alkyl (C<sub>14</sub>C<sub>12</sub>C<sub>16</sub>)  
22 trimethylbenzylammonium chloride. In addition to these organochlorides, other known  
23 antimicrobial agents may also be used as the active agent or in combination with the active  
24 agents provided above, for example, chemicals which are known to act as an antiviral,  
25 antibacterial or antifungal agents such as the antifungal agents disclosed by Chodosh in U.S.  
26 Patent No. 5,661,170 and U.S. Patent No. 5,827,870, which are hereby incorporated by

reference. Additional examples of effective organochloride that are comprised in additional embodiments of the present invention include dual quaternary ammonium compounds. These embodiments comprise at least two quaternary ammonium compounds.

One of such embodiments comprises a mixture of n-alkyl dimethyl benzyl ammonium chloride and n-dialkyl methyl benzyl ammonium chloride. One example of such embodiments is distributed by Stepan as BTC® 776 with a chain length distribution for the n-alkyl of about 60% C<sub>14</sub>, about 30% C<sub>16</sub>, about 5% C<sub>12</sub>, and about 5% C<sub>18</sub> (CAS Reg. No. 683991-10-5), and a chain length distribution for the n-dialkyl of about 60% C<sub>14</sub>, about 30% C<sub>16</sub>, about 5% C<sub>12</sub>, and about 5% C<sub>18</sub> (CAS Reg. No. 68391-05-9).

Another of such embodiments comprises a mixture of n-alkyl dimethyl benzyl ammonium chloride (I) and n-alkyl dimethyl ethylbenzyl ammonium chloride (II). One example of such embodiments is distributed by Stepan as BTC 2125®M series with a chain length distribution for the n-alkyl in entity (I) of about 60% C<sub>14</sub>, about 30% C<sub>16</sub>, about 5% C<sub>12</sub>, and about 5% C<sub>18</sub> (CAS Reg. No. 683991-10-5), and a chain length distribution in entity (II) of about 68% C<sub>12</sub>, and about 32% C<sub>14</sub> (CAS Reg. No. 68956-79-6).

Embodiments of the present invention are effective for treating disorders of human tissue that are caused by germs such as lipid coated viruses and skin pathogens. Reference to the U.S. Pharmacopoeia (USP) is made herein to describe constituents of embodiments of the present invention. Persons skilled in the art will recognize that other grades of constituents are possible, provided that they are validated against the USP quality standards where such validation is to be performed for their use in the treatment of human beings.

A preferred method of preparation involves taking 70% isopropyl rubbing alcohol USP (70% isopropanol, v/v, specific gravity 0.877 at 20°C, *see* 24 USP, p. 927) and then admixing the benzalkonium chloride, NF. Isopropyl alcohol USP (IPA) is available from any number of US sources including, but not limited to, Union Carbide, Aldrich Chemical, Texaco, and Shell. Purified Water USP is available from a variety of laboratory supply

1 houses, such as Aldrich Chemical, Fisher Scientific, and VWR Scientific. Purified Water  
2 USP can also be obtained by means of a commercially available water purification system  
3 designed to meet the requirements of purified water USP.

4 As an example, the preparation of what is herein termed 70% IPA is described  
5 below. This concentration is given by volume, and it is understood to be interpreted as  
6 follows. About 70 ml of isopropyl alcohol USP, specific gravity 0.785, are mixed with about  
7 30 ml of purified water USP, resulting in about 84.95 g, or 96.86 ml, of a product that has  
8 a specific gravity in the range from about 0.872 to about 0.883 at 20°C, with a target specific  
9 gravity of about 0.877 at 20°C. The corresponding concentration range by volume is from  
10 about 68% to about 72%, with a target of 70% by volume in accordance with the  
11 requirements at 24 USP, p. 927.

12 Testing the ratio in the admixture is done preferably according to the methods found  
13 at 24 USP p. 927. Those of ordinary skill in the art will recognize that other tests are  
14 possible, such as gas-liquid chromatography, provided proper validation is performed when  
15 the intended use is as a drug for human beings where such validation is required.

16 The preparation of a benzalkonium chloride solution with a concentration of about  
17 0.13% is preferably made by adding to isopropyl alcohol that is about 70% by volume an  
18 amount of benzalkonium chloride according to this product's activity, so that a solution of  
19 about 0.13% by weight of benzalkonium chloride is obtained. As indicated above,  
20 benzalkonium chloride is available from several primary manufacturers, such as Stepan  
21 Company, Mason Chemical Company, Lonza, and Huntington Labs., or from several  
22 distributors and suppliers, such as Aldrich Chemical, Van Waters & Rogers, and Fisher  
23 Scientific. The bulk ingredients are typically sold as about 50% active or 80% active.

24 Embodiments of the present invention include preparations with organohalide  
25 concentrations in the range from about 0.001% to about 2% by weight of the treatment  
26 composition. These concentration values also refer to preparations that include



1 benzalkonium chloride and where the active ingredient is not benzalkonium chloride, but one  
2 of the other substances herein disclosed as active ingredients and equivalents thereof.  
3 Furthermore, these concentration values also refer to the combined amounts of active  
4 ingredients when more than one active ingredient is present in other embodiments according  
5 to this invention, such as when the composition comprises dual quaternary ammonium  
6 compounds.

7 The amount of benzalkonium chloride by weight to be dissolved in 70% v/v  
8 isopropyl alcohol is calculated by multiplying the weight of 70% v/v isopropyl alcohol that  
9 is used by the weight concentration of benzalkonium chloride referred to one (this is, for  
10 example, 0.0013 in the case of a 0.13% by weight benzalkonium chloride solution), and  
11 further multiplied by the benzalkonium chloride activity referred to one (this is, for example,  
12 0.5 for a benzalkonium chloride activity of 50%). By way of example, the amount of  
13 benzalkonium chloride (activity of 50%) by weight that must be added to 84.95 g of  
14 isopropyl alcohol (70% v/v in water) to yield a solution that contains 0.13% by weight  
15 benzalkonium chloride is calculated by multiplying together 84.95g and 0.0013 and dividing  
16 the result by 0.5, which yields 0.22087 g benzalkonium chloride (50% activity) (*i.e.*,  $84.95$   
17  $\text{g} \times 0.0013 \div 0.5 = 0.22087 \text{ g}$ ). The constituents are mixed well until the mixture is uniform.

18 A plurality of qualitative and quantitative analytic methods are known for the  
19 analysis of the resulting benzalkonium chloride solution. Reference to 24 USP, pp. 2419-20  
20 is usually made in the context of drugs for human beings. Those of ordinary skill in the art  
21 will recognize that other methods are possible, such as those indicated by the manufacturers  
22 referred to above, nuclear magnetic resonance (NMR), and high performance liquid  
23 chromatography (HPLC).

24 When the anti-infective agent is benzalkonium chloride or other aromatic quaternary  
25 ammonium halide compound, the concentration within a topical composition is preferably  
26 in a range from about 0.01% and to about 0.5% by volume of the treatment composition,

1 more preferably in a range from about 0.05% to about 0.3% by volume of the treatment  
2 composition, and even more preferably in a range from about 0.1% to about 0.2 by volume  
3 of the treatment composition. To avoid toxicity, the concentration is less than 0.26% and is  
4 more preferably about 0.13% by volume of the treatment composition. Depending on the  
5 particular organohalide or quaternary ammonium chloride that is used as the active agent, the  
6 concentration may vary. For example, the concentration may range from about 0.001% to  
7 about 2% by volume of the treatment composition.

8 For the specialized treatment of the eyes, an eyewash having the active agent is made  
9 into a composition with an active agent concentration in the volume range from about  
10 0.001% to about 0.05 %. Preferably, the active agent concentration for an eyewash is in the  
11 range from about 0.005% to about 0.03%. Higher concentrations may be administered by  
12 a medical professional. The specialized treatment of the eyes may also require several  
13 treatments instead of a single, primary treatment. Where eye drops are used, according to  
14 the inventive method, the composition is deposited onto the eye and the patient closes the eye  
15 after the eye has been contacted with the composition, and the patient may opt to rub the  
16 eyeball through the eyelid to assist in the delivery of the treatment composition and the  
17 penetration into the eye tissue. If the disordered tissue is in a corner of the eye, it may even  
18 be vigorously agitated. A subsequent treatment and a series of subsequent treatments may  
19 also be carried out on the eyes.

20 As indicated above, the carrier is a vehicle for the biologically active agent, more  
21 particularly the anti-infective active agent. The carrier causes effective wetting and  
22 penetration of the tissue to be treated and then enables the anti-infective agent to move within  
23 this carrier into the disordered tissue.

24 In one embodiment, the treatment composition consists of only the active agent such  
25 as benzalkonium chloride and the carrier. In other embodiments, the treatment composition  
26 consists essentially of the active agent and the carrier, together with other components as

1 described hereinbelow. In any event, the carrier is preferably sufficiently inert with respect  
2 to the active agent and any other component present to enable the treatment composition to  
3 be stored for long periods of time without deactivating the anti-infective agent, such as at  
4 least 1 year and preferably at least 2 years.

5 The carrier preferably has properties which enhance the ability of the treatment  
6 composition to penetrate into the disordered epithelial tissue. More particularly, the carrier  
7 has a viscosity and/or density which is not significantly greater than that of water in order to  
8 optimally enable the treatment composition to penetrate into the disordered tissue. Using a  
9 carrier composition having a viscosity which is not significantly greater than that of water  
10 is in sharp contrast to conventional compositions which enable the composition to be coated  
11 onto afflicted tissue. Accordingly, the treatment compositions preferably exclude  
12 formulations which may be considered to be primarily or essentially gels, creams, lotions,  
13 oils, ointments, pastes, emulsions, and viscous colloidal suspensions. Note, however, that  
14 small amounts of inert abrasive material may be present in the treatment compositions as  
15 discussed hereinbelow. It will be appreciated that the carrier may include substances which  
16 have either a viscosity or density which is more than slightly greater than that of water as  
17 long as other substances are also included in the carrier such that the mixture has either a  
18 viscosity or density which is not significantly greater than that of water.

19 The carrier preferably has a tissue penetrating component such as isopropyl alcohol  
20 that is capable of penetrating the skin and cells in a rapid manner without rapidly diffusing  
21 beyond the skin into the body. More particularly, the carrier preferably enables the stratum  
22 spinosum 34 illustrated in Figure 1 to be saturated in the region of the cold sore or other  
23 disordered tissue for a period that enables the treatment composition to achieve its purpose  
24 before it diffuses into the body. In this way, the treatment composition forms a temporary  
25 reservoir (or bath) in the region where it is needed most. In this way, the treatment  
26 composition can maximize its effect of killing pathogens and/or destroying toxins within the

1 disordered tissue while minimizing possible damage to surrounding healthy tissues or the  
2 organism as a whole.

3 The carrier may be formed from a single liquid constituent such as isopropyl alcohol  
4 or water as described hereinbelow, or from more than one constituent. Although water alone  
5 may be used as the carrier, it is not preferred because other compounds, such as some  
6 alcohols, have a tissue penetrating capability that is superior to water. The carrier in the  
7 treatment composition is also preferably not formed entirely from an alcohol such as  
8 isopropyl alcohol or ethyl alcohol, since their use may be more painful in some  
9 circumstances. More particularly, when an open sore is part of the disordered tissue, the  
10 amount of alcohol or other composition that has a significant tissue penetrating ability may  
11 be modified by adding water so as to moderate the amount of discomfort that the patient  
12 experiences by the application of the composition to the open sore. Additionally, the  
13 evaporation rate of a carrier that includes alcohols such as isopropyl alcohol can be reduced  
14 by including water. Further, it may be preferred to use alcohols such as isopropyl alcohol  
15 with other constituents such as water due to regulatory issues. Also some substances, such  
16 as benzylkonium chloride, dissolve best in a carrier that includes water.

17 While isopropyl alcohol is a preferred carrier due to its ability to effectively  
18 penetrate tissue, other alcohols may also be used. In addition to isopropyl alcohol, ethanol  
19 and methanol are also suitable carriers. Benzyl alcohol can be used as a carrier or as an  
20 additive as it also acts as a bacteriostat and an anesthetic. Mixtures of the above-mentioned  
21 alcohols may also be used as desired depending upon the application. As indicated above,  
22 however, isopropyl alcohol or ethyl alcohol is preferably used in combination with other  
23 carrier constituents. For example, as mentioned above water may be added to isopropyl  
24 alcohol to reduce the pain which may be felt when only isopropyl alcohol is used. Similarly,  
25 isopropyl alcohol may be utilized with cetyl alcohol or with a combination of both cetyl  
26 alcohol and water to reduce the sensation.

1 As noted above, the carrier preferably has a tissue-penetrating constituent such as  
2 isopropyl alcohol. It has been noted that the ability of the treatment composition to penetrate  
3 disordered tissue is significantly enhanced when at least a portion of the carrier is isopropyl  
4 alcohol. While not being limited by any particularly theory, it is suggested that isopropyl  
5 alcohol opens cells and is not blocked by lipids or lipid layers in the disordered tissue.  
6 Accordingly, it is believed that isopropyl alcohol penetrates so effectively due to its ability  
7 to penetrate the lipid structure and cell wall of the tissue. The penetration ability of a carrier  
8 comprising isopropyl alcohol may be further enhanced by including a very small amount of  
9 ethyl alcohol such that the carrier is less than about 1% ethyl alcohol.

10 As indicated above, the preferred carrier includes isopropyl alcohol and water. As  
11 also discussed above, isopropyl alcohol is included in the carrier for its ability to rapidly  
12 penetrate disordered tissue while the water is included primarily to minimize the sensation  
13 which may be felt as the isopropyl alcohol penetrates the skin. While substances like  
14 lidocaine and other substances that have anesthetic qualities can be used instead of water to  
15 reduce the sensation caused by isopropyl alcohol, the carrier preferably includes water with  
16 the isopropyl alcohol as benzalkonium chloride dissolves more easily in such a combination  
17 than in isopropyl alcohol alone. It is also simpler to use a carrier that includes both isopropyl  
18 alcohol and water than it is to pretreat the disordered tissue with an anesthetic composition.  
19 However, pretreating the disordered tissue with an anesthetic composition is also within the  
20 scope of the present invention.

21 Carriers that include isopropyl alcohol and water have varying ratios depending on  
22 the intended use. However, for treating cold sores the water is preferably included in a  
23 range from about 10% to about 50% by volume of the carrier with the remainder being  
24 isopropyl alcohol. The water content is more preferably in a range from about 20% to about  
25 40% by volume of the carrier. The most preferred carrier for treating cold sores is a carrier  
26 in which water is included in an amount of about 30% by volume of the carrier and wherein

1 the isopropyl alcohol is included in an amount of about 70%. Although, these ranges of  
2 water content are provided based on the volume of water in the carrier, essentially the same  
3 water contents apply to the overall treatment composition since the other active agent and  
4 any other optional component are typically included in such small amounts. For example,  
5 the most preferred composition is a treatment composition including about 0.133%  
6 benzalkonium chloride by volume of the treatment composition, 29.987% water by volume  
7 of the treatment composition and 70% isopropyl alcohol by volume of the treatment  
8 composition. Embodiments of preparations according to the present invention include a  
9 carrier that comprises an alcohol, preferably isopropyl alcohol, at a concentration by volume  
10 in the range from about 20% to about 80%.

11 When treating sensitive parts of the body such as the genitalia and adjacent areas,  
12 the carrier may include isopropyl alcohol in an amount of about 10 to about 15% by volume  
13 of the carrier and water in an amount of about 85% to about 90%. However, as noted above,  
14 higher concentrations can still be used even in sensitive areas, particularly when pretreated  
15 with an anesthetic composition.

16 While rapid penetration is desired, it should be understood that the objective is rapid  
17 penetration through the skin so as to form a subcutaneous reservoir (or bath) of the treatment  
18 composition in the spiked or horned cells shown as element 34 in Figure 1. In the case of  
19 herpes or other viruses that reside in the nerves, it may be desirable for the treatment  
20 composition to penetrate through the subcutaneous layers to the infected nerve without  
21 thereafter rapidly passing into the blood stream. Accordingly, the carrier preferably does not  
22 include substances, or at least not large quantities of substances, such as dimethyl sulfoxide  
23 (DMSO) that immediately penetrate the skin and enter the blood stream. In general, it is  
24 desirable for the treatment composition to reside for a length of time sufficient to maintain  
25 the desired activity until it slowly diffuses out and is carried away.

1           The carrier may also include other solvents such as acetone, acetic acid, acetic  
2 anhydride, and the like. However, if acetone and the like are used they are preferably used  
3 in smaller quantities and not as the sole constituent as they may evaporate too rapidly and do  
4 not penetrate the skin and cells as well as isopropyl alcohol. While such solvents may not  
5 be as effective as certain alcohols, particularly isopropyl alcohol, acetone does exhibit some  
6 ability to penetrate tissue. So although solvents such as acetone may be used alone, it is  
7 preferably used in combination with other substances. One preferred carrier combination is  
8 ethanol and acetone in a ratio of about 70% ethanol by volume of the carrier, preferably 80%  
9 ethanol and most preferably about 90% ethanol with 10% acetone by volume of the carrier.  
10 As mentioned above with respect to the water content for carriers formed from water and  
11 alcohol, the ratios provided for combinations of ethanol and acetone based on the volume of  
12 the carrier apply also to the volume of the treatment composition.

13           The above carriers may also be combined across class lines. As such, the carriers  
14 such as water, alcohols, and other solvent compounds may be combined. One example is  
15 water, alcohol, and acetone in respective amounts of 30%, 60%, and 10%, by volume of the  
16 carrier. Generally speaking, the constituents may be combined in any suitable ratio such as:  
17 1:1:0, 1:2:0, 1:10:0, 1:1:1, 1:2:1, 1:10:1, 1:10:10, and 1:2:10.

18           As indicated above, the carrier is preferably a liquid that includes alcohol as it is  
19 believed that alcohols included in sufficient quantity to act as the carrier may have the quality  
20 of removing lipids from the tissue and thereby enabling the active agent to move within the  
21 disordered tissue. It is also believed that the ability of the treatment composition to penetrate  
22 the disordered tissue is hindered by including components in the composition such as oils or  
23 materials which have traditionally been included to enable the composition to be coated onto  
24 the surface of the disordered tissue. Examples of such materials include petrolatum which  
25 is used in various cold sore treatment compositions. For example, the popular over-the-  
26 counter lip ointment sold under the trademark *BLISTEX* by Blistex Incorporated of

1 Oakbrook, Ill. 60521. The *BLISTEX* ointment contains allantoin (1%), camphor (0.5%) and  
2 phenol (0.5%) in an emollient base with petrolatum, lanolin, menthol, methyl salicylate, and  
3 other ingredients. Other widely used ingredients that are included to increase the viscosity  
4 or to increase the tackiness includes polyethylene glycol and polypropylene glycol. An  
5 example of a product which utilizes polyethylene glycol and polypropylene glycol is a gel  
6 sold under the trademark *ORAGEL* MOUTH AID by Del Laboratories Incorporated of  
7 Farmingdale, NY 11735. Other thickeners are taught in U.S. Patent No. 5,661,170, which  
8 was previously incorporated by reference, as including cellulosic materials and waxes. In  
9 addition to petrolatum based materials and thickeners, it is also believed that materials which  
10 are either obtained from natural sources such as naturally occurring oils present in trees,  
11 bushes, plants, etc. or substances which are derived from such oils may also reduce the  
12 ability of the treatment composition to penetrate the disordered tissue. Such materials are  
13 referred to herein as penetration inhibiting components.

14 The carrier may also include other components that, by themselves, may be too  
15 viscous to act as tissue penetrating agents, but which, in combination with water, isopropyl  
16 alcohol, and other solvents identified above, can actually enhance penetration. Such  
17 components may be classified as "auxiliary penetrating components", examples of which  
18 include, but are not limited to, ethoxylated alcohols (*e.g.*, lauryl alcohol ethoxylates),  
19 ethoxylated nonylphenols (*e.g.*, Nonoxynol-9), low molecular weight glycols (*e.g.*, ranging  
20 from ethylene glycol to PEG-400, propylene glycol, propanediol, and the like), and  
21 ethoxylated amines (*e.g.*, amine quaternaries). Certain essential oils and emollients, which  
22 are normally water insoluble, can be made soluble in water by ethoxylation (*e.g.*, ethoxylated  
23 lanolin). In quantities less than about 10% by volume, the foregoing do not increase the  
24 viscosity of the carrier and can assist in penetrating the tissue, though they are not as efficient  
25 as alcohols such as isopropyl alcohol and ethanol.



1 As indicated above, penetration inhibiting components includes chemicals which are  
2 petrolatum based substances, materials conventionally utilized as thickeners, naturally  
3 occurring oils, substances derived from naturally occurring oils or any other substance which  
4 is added primarily to increase the tendency of a treatment composition to remain on the  
5 surface of disordered tissue such as a cold sore. Note that while substances such as  
6 petrolatum or thickeners are not added individually, a component may be added which  
7 includes minute amounts of naturally occurring oils or substances derived from oils obtained  
8 from natural sources. So although, the inventive composition is preferably substantially oil  
9 free, the term "substantially oil free," is meant that oil substances are preferably not  
10 individually added, but may be present due to the natural content of a substance added to the  
11 inventive composition. As such, oil may be incidentally present in an amount of less than  
12 about 2% by volume, and is preferably incidentally present in an amount of less than about  
13 1%, and is most preferably incidentally present in an amount less than about 0.05% and even  
14 more so at an amount less than about 0.01%. Additionally, in some instances it may be  
15 desirable to add very small quantities of naturally occurring oils or substances; however, the  
16 concentration is no more than the incidental amounts discussed above.

17 Note that penetration inhibiting components are believed to act as a barrier which  
18 seals in toxic irritating by-products of viral growth. They prevent the natural weeping  
19 process of the disordered tissue which flows to remove toxins, etc. Accordingly, use of such  
20 penetration inhibiting components may actually cause more damage to the disordered tissue  
21 despite the temporary advantages achieved though using such substances.

22 As indicated above, the treatment composition may consist of only the active agent  
23 and the carrier. Treatment compositions consisting essentially of the active agent and the  
24 carrier do not include penetration inhibiting substances but may include other components  
25 added for specific purposes. These components or additives are added to achieve a particular  
26 result and do not have a substantial impact on the ability of the treatment composition to

1 penetrate into the disordered tissue or the ability of the treatment composition to be anti-  
2 infective. Examples of such components are additives which are conventionally used as  
3 preservatives, pH adjusters, substances having anesthetic qualities, vasodilators, analgesics  
4 and defoamers. These components or additives are used in concentrations which correspond  
5 with amounts conventionally utilized.

6 Generally, preservatives may be added to the anti-infective composition. Examples  
7 of preferred preservatives include parabens, preferably methyl and propyl parabens.  
8 Preferably the preservatives, if present, are included in the composition in a range from about  
9 0.0001% to about 0.01% by volume of the treatment composition.

10 Additives such as those set forth above can be blended with other ingredients to  
11 make up the inventive composition including pH adjustors. Such pH adjustors may include  
12 organic acids, mineral acids in minute amounts, organic bases or mineral bases also in  
13 minute amounts. Preferred organic acids include acetic acid, caproic acid, and the like, and  
14 combinations thereof. When other organic acids do not cause undesirable effects, such as  
15 chelation, on the active ingredients of embodiments according to this invention, they can also  
16 be used as such pH adjustors, and such acids include citric acid, ascorbic acid, sorbic acid,  
17 malic acid, succinic acid, and combinations thereof. Other preferred acids include  
18 hydrochloric acid, nitric acid, hydroiodic acid, and the like in minute amounts. Preferred  
19 bases include methyl and ethylamines such as triethanolamine, and the like. Other preferred  
20 bases include, ammonium hydroxide, potassium hydroxide, sodium hydroxide, and the like.

21 The inventive compositions may include compounds with anesthetic qualities.  
22 Depending upon the application site, whether on dermal layers or on mucous membranes,  
23 different anesthetics may be preferred. One particularly preferred anesthetic is benzocaine.  
24 Benzocaine is especially useful in the areas of open sores such as cold sores, eczema sores,  
25 and the like. Of the amides, such compounds as bupivocaine, carbocaine, and ropivocaine  
26 may be preferred. Of the esters, such compounds as procaine, cocaine, novocaine, tetracaine,

1 and benzocaine may be preferred. Other preferred anesthetics include alkaloids such as  
2 cocaine, caffeine, nicotine, xylocaine, and the like. Another preferred anesthetic includes a  
3 combination of lidocaine HCl and prilocaine. With these two compounds, an eutectic  
4 mixture is achieved with a melting point below room temperature. A preferred composition  
5 of the lidocaine and prilocaine is about 2.5 % each in a 1:1 mixture. Other preferred  
6 anesthetics include oil of cloves, tea tree oil (*melaleuca alternifolia*, which also acts as a  
7 disinfectant) and the like. Other preferred anesthetics include lidocaine hydrochloride,  
8 dibucaine, dibucaine hydrochloride, tetracaine hydrochloride, tronothane, dyclonine,  
9 dyclonine hydrochloride, pramoxine hydrochloride, diperodon, butamben picrate,  
10 cyclomethycaine sulfate, cyclomethycaine hydrochloride, and dimethisoquin hydrochloride.  
11 Where an anesthetic is present, it is included in an amount in a range from about 0.001% to  
12 about 2% by volume of the treatment composition.

13 Other preferred components for the inventive composition include vasodilators, such  
14 as nitroglycerine and the like. Vasodilators are useful for causing penetration of the active  
15 agent or agents into the disordered tissue to its base in the skin or mucous membranes an  
16 beyond. Care must be taken to balance the effect of localized vasodilation against the  
17 systemic toxicity of the inventive composition such that penetration into the disordered tissue  
18 is clinically significant, but that the active agent or agents remain substantially local to the  
19 disordered tissue for maximum efficacy. Where a vasodilator is supplied to make up the  
20 inventive composition, it may be provided in a preferred range from about 0.001% to about  
21 0.05% by volume of the treatment composition.

22 Other preferred components for the inventive composition include analgesics such  
23 as methyl salicylate, aspirin, and other salicylate salts. Other preferred components for their  
24 analgesic effects include N,N-dimethyl aspartic acid; N-N-dimethyl glutamic acid, trolamine  
25 salicylate, antipyrine, and salicylamide. Where an analgesic is present, it may be included  
26 in a preferred range of about 0.001% to about 2% by volume of the treatment composition.

1 Many of the active agents disclosed above are considered to be cationic surfactants  
2 so it is generally unnecessary to include any surfactants. It is also generally unnecessary to  
3 include surfactants as the treatment composition is substantially oil free. Additionally, the  
4 active agent can be used with various carriers so the carrier can be modified to achieve  
5 optimal solubility as needed. To the extent that a surfactant is included, for example, to  
6 assist in tissue wetting properties, the surfactants may be cationic, nonionic, and  
7 combinations thereof. In some circumstances it may be useful to use other surfactants such  
8 as another cationic surfactant. U.S. Patent No. 5,661,170, referenced above, may be referred  
9 to for a disclosure of suitable surfactants. Anionic surfactants are generally less desirable  
10 because they tend to deactivate benzalkonium chloride, rendering it bio-unavailable.  
11 Amphoteric surfactants, which contain both cationic and anionic functionality, can work so  
12 long as the pH is controlled so that the anionic functionality does not deactivate the  
13 benzalkonium chloride. To the extent that an anionic surfactant can be made to work without  
14 deactivating benzalkonium chloride, however, such as by controlling the pH, it is certainly  
15 within the scope of the invention to use such surfactants.

16 Abrasives are generally not necessary as a component of the composition as the  
17 applicators are configured for abrasion. Additionally, when irritating an open sore it is  
18 generally undesirable for abrasives to be deposited into the open sore. Nor is it generally  
19 necessary to include abrasives on the applicators, which also risks the abrasives being  
20 dislodged from the applicator and placed into an open sore. However, this does not exclude  
21 the use of abrasives as free-floating inert components in a treatment composition nor their  
22 surface attachment to or impregnation in an applicator. If used, suitable abrasives may  
23 include pumice and the like as well as oxides such as alumina, silica, mica, zirconia, titania  
24 (both anatase and rutile), and the like.

25 In making a mixture of any of the preceding carriers and additives, it is understood  
26 that the recitation of compounds as mixtures includes the solution and reaction products

1 thereof. A preferred method for preparing the inventive composition is to dissolve the anti-  
2 infective active agent into the carrier, such as to dissolve benzalkonium chloride in isopropyl  
3 alcohol. In general, it is only necessary to mix the agent, such as benzalkonium chloride, into  
4 the carrier. In some instances, it may be helpful to first lower the pH of the solution into a  
5 range preferred to assist the dissolution of selected components. Note that benzalkonium  
6 chloride are generally acidic but can be made alkaline by adding pH adjusters. Following  
7 dissolution of the selected components that are assisted in their dissolution by a lower pH,  
8 the solution may be either warmed or the pH increased, or both, and other components may  
9 be added, preceding or following the warming and/or the pH increase.

10 The use of soap is preferably avoided in the inventive method as it tends to  
11 significantly reduce the efficacy of the methodology. However, the inventive method may  
12 include a precleaning step that comprises washing the disordered tissue treatment site. The  
13 precleaning step may include the use of a pre-moistened, organohalide impregnated  
14 towelette. Commercially available towelettes are preferably not used as these towelettes  
15 contain components which are generally considered undesirable in combination with the  
16 present invention. Accordingly, when a precleaning towelette is used, it is preferred that the  
17 towelette be moistened with a composition which does not contain any penetration inhibiting  
18 components such as lanolin. An example of a commercially available towelette is the PDI®  
19 towelette made by Professional Disposables, Inc. of Orangeburg, New York which is  
20 impregnated with benzalkonium chloride. Another example is the WET ONES® towelette  
21 made by Playtex Products, Inc. of Dover, Delaware which is pre-moistened, benzethonium  
22 chloride impregnated towelette.

23 In one method of the present invention, a topical anesthetic may be applied to the  
24 treatment site and enough time may be allowed to elapse in order to substantially anesthetize  
25 the nerve endings for disordered tissue and surrounding tissue at and near the treatment site.  
26 For example, towelettes may also be used that are impregnated with anesthetics to reduce the

1 sensitivity of an area that is to be treated with vigorous agitation. After sufficient  
2 anesthetization of the treatment site, the inventive method continues by providing the  
3 inventive composition that contains the anti-infective agent followed by impregnating an  
4 applicator with the composition, or using a pre-impregnated applicator. Finally, the  
5 disordered tissue at the treatment site is vigorously agitated with the applicator while  
6 contacting the disordered tissue with the composition. According to this alternative  
7 inventive method, where a patient may have a low threshold of pain tolerance, the  
8 preliminary anesthetization of disordered tissue at and near the treatment site allows for the  
9 vigorous irritation of the disordered tissue without the accompanying discomfort.

10 Another alternative includes the application of a substance in liquid form in order  
11 to provide both sterile and cosmetic covering of the disordered tissue after the inventive  
12 vigorous agitation treatment. One example of a suitable liquid is NEW-SKIN® Liquid  
13 Bandage made by Medtech Laboratories, Inc. of Jackson, Wyoming.

14 Applicators are preferably part of the inventive method and system. As such,  
15 applicators may be preconfigured with particular mixtures to treat specific disorders such as  
16 cold sores, eczema, and the like. Applicators are well known in the art. Examples thereof  
17 include those taught by Booras et al. in U.S. Patent No. 5,709,866; by Fox in U.S. Patent  
18 No. 5,704,906; by Mythling in U.S. Patent No. 5,527,534; by Stalcup et al. in  
19 U.S. Patent No. 5,016,651; by Bedford in U.S. Patent No. 4,887,994; and by Korteweg in  
20 U.S. Patent No. 4,952,204; the disclosures of which are incorporated herein by specific  
21 reference. Preferred applicators include prepackaged applicators that have agitation pads  
22 impregnated with the inventive composition. An applicator may be provided as a unitary  
23 structure such as a sealed container that is frangible and configured for a single use.

24 Applicator are preferably configured to enable the treatment composition to be either  
25 delivered with vigorous agitation or to be merely delivered onto the disordered tissue. Such  
26 flexibility is useful since tissue disorders such as cold sores typically progresses in stages that

1 have varying pain thresholds. Whether the applicator is designed to vigorously agitate the  
2 disordered tissue or not, the applicator is preferably able to deliver large volumes of the  
3 treatment composition onto the disordered tissue. The delivery of large volumes of the  
4 treatment composition may be achieved in several different ways. Applicators are also  
5 disclosed, however, that can only hold relatively small quantities of the treatment  
6 composition.

7 FIGS. 2A-2E depict a preferred applicator 10. The details of applicator 10 are best  
8 seen in Figure 2A which is an exploded perspective view, Figure 2B a perspective view of  
9 the assembled applicator and Figure 2C as it appears when ready for application.

10 Applicator 10 includes an absorbent, agitation pad 12, that is abutted against a  
11 frangible ampule or reservoir 14 via open delivery end 17 of the flexible container 16.  
12 Frangible reservoir 14 is housed in a container 16 that forms a holder for agitation pad 12.  
13 Frangible reservoir is enclosed by agitation pad 12, the sidewalls of container 16 and the  
14 closed end 19 of container 16. Frangible reservoir 14 is preferably a thin glass ampule while  
15 container 16 is preferably formed from a flexible plastic. A protective sleeve 18 is provided  
16 that is designed to keep agitation pad 12 free from contamination until applicator 10 is ready  
17 for use on the disordered tissue. A cap 20 is provided to fit into sleeve 18. The treatment  
18 composition 22 is held in frangible reservoir 14 until such time as frangible reservoir 14 is  
19 to be broken. One source for applicators having a frangible reservoir and various pad  
20 configurations is James Alexander Corporation of Blairtown, New Jersey.

21 Figure 2C is a perspective view of the preferred applicator depicted in Figure 2B  
22 after frangible reservoir 14 has been ruptured. Treatment composition 22 is allowed to  
23 permeate agitation pad 12 in preparation for vigorous application to a disordered tissue  
24 treatment site. In Figure 2C, sleeve 18 has been removed to expose an impregnated agitation  
25 pad 12. After impregnated agitation pad 12 is sufficiently wetted, application to the  
26 disordered tissue treatment site may commence.

Figure 2D is a perspective view of an individual 26 applying treatment composition 22 to a cold sore at or near the lip according to the present invention. Figure 2D illustrates that sufficient pressure is being applied against a non-puckered lip as the lip is pressed against the patient's teeth and/or gums in order to direct focused pressure into the disordered tissue while the active compounds are expressed from impregnated agitation pad 12 and into the disordered tissue. The combined effect of vigorous irritation of the disordered tissue and the administration of treatment composition 22 has the result of surprising therapeutic effects.

Figure 2E is a detail taken along the section line 2E-2E in Figure 2D that depicts a close-up view of the inventive method. The detail view more clearly illustrates vigorous agitation of the disordered tissue site where impregnated agitation pad 12 is being pressed into the lip in order to be firmly felt at the gums or teeth opposite the disordered tissue. The arrows illustrate directions of agitation movement by way of non-limiting example.

Pad 12 has several purposes. Once frangible reservoir 14 is ruptured the treatment composition is delivered to pad 12 as gravity enables it to flow into pad 12, however, rupturing frangible reservoir 14 creates shards of glass. Pad 12 prevents these shards from passing and causing injury as the pad is used to deliver the composition to the disordered tissue. Another purpose of pad 12 is obviously the delivery of the treatment composition so the pad has a certain mesh or configuration that enables it to hold and deliver the treatment composition due to either porosity, capillary action, etc. As discussed above in reference to Figure 2D, as pad 12 delivers the treatment composition it is also preferably used to vigorously agitate the disordered tissue.

Many configurations are available for a pad such as those disclosed in U.S. Patent No. 1,822,566 and French Patent No. 2,700,698. The pad must of course be configured to prevent the passage of shards of glass out of container 16 and to enable treatment composition 22 to be held and delivered. The pad also preferably is configured for



1 vigorously agitating the disordered tissue. Features that enable pad 12 to be used in  
2 vigorously agitating the disordered tissue are discussed below.

3 Pad 12 is a folded sheet formed from a web of fibers. Figure 2F depicts sheet 12'  
4 before it has been folded or collapsed to form pad 12. As shown in Figure 2F, the sheet has  
5 a fluted appearance in order to provide an alignment such that when the sheet is gathered  
6 together in a bundle, it has longitudinal flutes. These longitudinal flutes provide a flow path  
7 for treatment composition 22 while the interlocked web of fibers prevents the shards of glass  
8 from passing out of container 16. Pad 12 has a configuration that is similar or identical to  
9 that of a cigarette filter. Examples of cigarette filters configurations that may be utilized are  
10 disclosed in U.S. Patent No. 5,465,739 and U.S. Patent 5,998,500, both of which are hereby  
11 incorporated by reference.

12 Pad 12 is preferably made of synthetic fibers that have a mesh which enables it to  
13 hold treatment composition 22 while having sufficient roughness to allow vigorous or  
14 continual agitation of the disordered tissue to enhance penetration by treatment composition  
15 22. The fibers forming pad 12 are relatively densely positioned and are also relatively rigid.  
16 The dense positioning and the rigid nature of the fibers enables applicator 10 to be used to  
17 vigorously agitate the disordered tissue. Note that applicator 10 is not used like a brush to  
18 merely apply the treatment composition like conventional methodologies which involve  
19 coating the afflicted tissue. If the fibers are relatively soft such that they flex significantly  
20 when pushed against the disordered tissue then it is necessary to also push relatively hard  
21 against the disordered tissue in order to insure that the disordered tissue has been adequately  
22 agitated. Accordingly, the fibers are preferably relatively rigid through either proper  
23 selection of the fiber material, the length of the fibers and/or the positioning of the fibers.

24 Pad 12 has a retention portion 13 positioned within flexible container 16. Retention  
25 portion 16 is preferably attached to flexible container 16 through use of an appropriate  
26 adhesive that remains inert in the presence of the treatment composition or through heat

1 fusing retention portion 13 and flexible container 16 together. Pad 12 also has a delivery  
2 portion 14 opposite from retention portion 16 that extends beyond open delivery end 17 of  
3 the flexible container 16. Regardless of the configuration of pad 12 or the material from  
4 which it is formed, the delivery portion is adapted to deliver the treatment composition to the  
5 disordered tissue while vigorously agitating the disordered tissue to enhance penetration of  
6 the treatment composition into the disordered tissue such that the treatment composition is  
7 no longer visibly detectable on the disordered tissue within several minutes after delivery of  
8 the treatment composition onto the disordered tissue.

9 Delivery portion 17 terminates at an agitation surface 15 that is relatively flat such  
10 that the disordered tissue is uniformly contacted. Uniformly contacting the disordered tissue  
11 with the flat surface reduces the risk of injuring the disordered tissue as the disordered tissue  
12 is vigorously agitated. Use of such a pad is to be contrasted with the use of a pad having a  
13 delivery portion that is bulbous such as a swab used in some applicators having a frangible  
14 ampule as disclosed in U.S. Patent No. 1,822,566 and French Patent No. 2,700,698. A  
15 bulbous swab may tend to provide either insufficient contact when lightly pressed or uneven  
16 pressure when pushed hard enough to vigorously agitate the disordered tissue. Although use  
17 of such a bulbous swab in place of a pad such as pad 12 may result in these disadvantages,  
18 such swabs may be used in certain circumstances.

19 The fibers used in pad 12 are preferably formed from polyester as such polyester  
20 fibers provide adequate stiffness at the desired length. Pad 12 may also be formed from  
21 polyolefin, porous polyethylene or a laminated polyester foam. As used in the specification  
22 and the appended claims, the term "fibers" includes both synthetic fibers, inorganic fibers,  
23 naturally occurring organic fibers and treated organic fibers. As indicated above, synthetic  
24 fibers such polyester fibers are preferred. Another example of synthetic fibers includes  
25 polyethylene fibers. Polyethylene fibers having the same length and diameter as polyester  
26 fibers are not as preferred as they tend be softer. Of course the abrasiveness of fibers can be

1 increased by increasing the diameter of the fiber; however, it is preferred not to increase the  
2 diameter of the fibers as this results in a decrease in surface area for the treatment  
3 composition to move downward on the fibers. Examples of inorganic fibers include glass,  
4 silica, ceramic, graphite, metal fibers, and mixtures thereof. Any fiber which has the  
5 preferred physical qualities such as strength, roughness, ability to hold liquids, and/or proper  
6 flexibility is also within the scope of the present invention. The only limiting criteria is that  
7 the fibers be able to be configured in a manner that enables them to hold the treatment  
8 composition and agitate the afflicted tissue without adversely reacting with the chemical  
9 constituents of treatment composition 22. Examples of naturally occurring fibers, include  
10 cellulosic fibers extracted from abaca, bagasse, hemp, cotton, plant leaves, wood or stems.  
11 The wood fibers may be both hard wood or soft wood, such as southern pine. While pad 12  
12 may be made of such organic or naturally occurring fibers, it may be necessary to treat some  
13 naturally occurring fibers as discussed hereinbelow.

14 The retention portion of pad has a length that is sufficient for the pad to be securely  
15 anchored in the open delivery end of the container. The delivery portion has a length and  
16 sufficient rigidity to enable the agitation surface to scrub the disordered tissue. When the pad  
17 is formed by folding or compressing together a sheet that is a polyester fiber web as shown  
18 in Figure 2F at 12', the retention portion preferably has a length ranging from about 5 mm  
19 to about 7 mm and the delivery portion preferably has a length ranging from about 3 mm to  
20 about 5 mm. The length of the retention portion is more preferably about 6 mm and the  
21 length of the delivery portion is more preferably 4 mm. However, these lengths depend on  
22 the particular material so the delivery portion may merely range in length from about 1 mm  
23 to about 3 mm.

24 The diameter of the pad is preferably about 7 mm to about 1 cm, and is most  
25 preferably about 8 mm. This diameter is sufficiently large to enable large amounts of  
26 treatment composition to be delivered and provides sufficient surface area to contact a cold

1 sore or other disordered tissue as need. More particularly, a pad diameter that roughly  
2 corresponds with the diameter of a cold sore in its various stages of development is ideally  
3 configured to vigorously agitate the cold sore treatment site.

4 In addition to a pad that is a folded sheet formed from a web of fibers, the pad may  
5 also be formed from a cluster of aligned bristles. Factors related to selecting appropriate  
6 bristles include the rigidity and flexibility of the bristles based on the properties of the  
7 material used to form the bristles, the length of the bristles especially the delivery portion,  
8 and the diameter of the bristles. Another factor is the diameter of the cluster. All of these  
9 factors are balanced so that the cluster of aligned bristles enables the treatment composition  
10 to be delivered while preventing passage of glass shards and so that the cluster of aligned  
11 bristles may be used in a scrubbing action. So while the cluster of aligned bristles may be  
12 held in place much like a brush and may be configured to brush the composition onto the  
13 disordered tissue, the bristles are preferably sufficiently rigid for scrubbing the disordered  
14 tissue as the treatment composition is delivered. Such rigidity is preferably achieved through  
15 selecting a material, such as nylon, that is relatively rigid even when the bristle formed from  
16 the material has a relatively small diameter. Use of bristles having relatively small diameters  
17 is preferred to enable the cluster to scrub while minimizing any potential for injuring the  
18 disordered tissue. For example if the bristles are formed from nylon and are about 1 cm long  
19 so that the retention portion and the delivery portion are each about 5 mm long then the  
20 diameter may range from about 0.1 mm to about 0.2 mm, and is more preferably 0.15 mm.

21 Note that the treatment composition flows more easily through a pad that is a cluster  
22 of bristles than it does through a compressed sheet formed from a web of fibers. Also, less  
23 treatment composition is retained by a cluster of bristles. Accordingly, the frangible ampule  
24 need not contain as much treatment composition when the pad is a cluster of bristles.

25 An advantage of applicator 10 is that frangible reservoir 14 holds a relatively large  
26 volume of the treatment composition so that the treatment composition is delivered in an

1 amount that is relatively large compared with the surface area to be treated. Further, the  
2 delivery is rapidly achieved due to the design of applicator 10 without requiring rewetting  
3 of pad 12 as the treatment composition is continually delivered to pad 12 until it is all used.  
4 For example, frangible reservoir 14 may deliver about 0.2 ml to about 1 ml to an area that  
5 is no greater than about 1 cm<sup>2</sup>. Accordingly, the volume to surface area ratio is preferably  
6 in a range from about 0.2 ml/cm<sup>2</sup> to about 1 ml/cm<sup>2</sup>. Such quantities are ideally sufficient  
7 to saturate the stratum spinosum 34 in the region of the cold sore or other disordered tissue  
8 so that it is available as a protective bath around the nerve. In any event, the treatment  
9 composition is preferably delivered in sufficiently large quantities that the disordered tissue  
10 at least appears moist and preferably such that the treatment composition pools initially on  
11 the surface of the disordered tissue. As indicated above, the penetrating capabilities of the  
12 treatment composition enables it to be no longer visibly detectable on the disordered tissue  
13 within several minutes after delivery of the treatment composition onto the disordered tissue.

14 A suggested application procedure using applicator 10 is to apply the .6 ml of the  
15 treatment composition for 30 seconds or longer, preferably while vigorously agitating the  
16 skin. Typical pain relief is within minutes. It may also be advantageous, especially during  
17 the prodromal stage, to deliver half of the treatment composition while rubbing the cold sore  
18 or other disordered tissue for about 30 seconds, wait about 1 minute and then deliver the  
19 remainder while rubbing for about 30 seconds again. Typically a single application is all that  
20 is required per outbreak, if the pain is not gone, or healing started in 24 hours then the  
21 treatment composition should be reapplied.

22 Another preferred applicator is illustrated in Figure 3. Figure 3 is a cross-sectional  
23 elevational view of an applicator 210 that may be part of the inventive system and method.  
24 Applicator 210 includes an absorbent agitation pad 212 that may be typical of a sterile  
25 adhesive bandage. Applicator 210 also includes adhesive wings 214 that may have adhesive  
26 typical of a sterile adhesive bandage. A separate strip acts as a container 216 in order to

1 cause treatment composition 22 to remain in agitation pad 212 until container 216 is stripped  
2 away from adhesive wings 214 of applicator 210. In addition thereto, a finger loop 228 that  
3 may include finger loop folds 230 and a finger loop tab 232 is attached to applicator 210  
4 immediately above agitation pad 212. Finger loop 228 is configured to lie flat against  
5 adhesive wings 214 and can be opened by lifting on finger loop tab 232 and hinge open at  
6 finger loop folds 230. Applicator 210 may be applied to a treatment site as typical of a  
7 sterile adhesive bandage and left in place indefinitely. Additionally, after a selected time  
8 period of having applicator 210, particularly agitation pad 212, upon a treatment site, the  
9 medical professional or the patient may grab the adhesive wing tabs 234, and gently pull  
10 adhesive wings 214 away from the skin. Meanwhile, the medical professional or the patient  
11 may insert a finger into finger loop 228, draw adhesive wings 214 also toward finger loop  
12 228 and commence to vigorously agitate the disordered tissue.

13 Where it is preferable to immediately agitate the cold sore, applicator 210 may be  
14 applied at the point of agitation pad 212 onto the disordered tissue and then vigorously  
15 agitated against the disordered tissue. Thereafter, applicator 210 may be discarded or  
16 adhesive wings 214 may be applied to the patient's skin to allow applicator 210 to remain  
17 over the disordered tissue. This alternative may be preferable where bleeding is incidental  
18 to the inventive method. As such, applicator 210 doubles as an adhesive sterile bandage.

19 In summary, applicator 210 may be used for vigorous irritation of the disordered  
20 tissue or merely as a delivery applicator. It may be used initially for application of the anti-  
21 infective active agent without vigorous irritation of the disordered tissue which is then  
22 followed by vigorous irritation of the disordered tissue. Vigorous irritation by applicator 210  
23 of the disordered tissue may be alternatively followed by leaving applicator 210 in place like  
24 a sterile adhesive bandage.

25 Figure 4 depicts another applicator at 310 in an elevational side view which may be  
26 used in an alternative embodiment of the present invention. The applicator or cotton swab

1 depicted at 310 has a swab agitation pad 312 upon a stem 314. Stem 314 may be formed  
2 from any suitable material, however, it is preferably relatively rigid to enable agitation pad  
3 312 to be pushed and/or moved in the desired manner. Pad 312 is preferably used such that  
4 the side thereof is pushed against the disordered tissue and not the bulbous tip. The side is  
5 used so that sufficient pressure can be applied while using the tip presents certain difficulties.  
6 More particularly, when significant pressure is applied, the bulbous tip is likely to dig into  
7 the disordered tissue while the surrounding area receives less pressure. Additionally, use of  
8 the bulbous tip results in a smaller surface area being contacted which may require agitating  
9 different portions sequentially.

10 It is preferable that the use of swab agitation pad 312 be used under substantially  
11 sterile conditions so as to not introduce pathogenic elements into the treatment site of the  
12 disordered tissue. The sterile agitation pad of the swab may be dipped into the inventive  
13 composition and then used to abrade the skin. More preferably, the swab is held in a bag as  
14 shown at 330 which also holds a burst pouch as shown at 340. Burst pouch 340 holds the  
15 treatment composition and is sized and/or positioned within the bag such that upon bursting  
16 it saturates the cotton swab. An example of a bag holding a swab and a burst pouch designed  
17 to be frangible is disclosed in U.S. Patent No. 5,709,866 to Booras, which was previously  
18 referenced.

19 An applicator and a burst pouch may also be held in separate compartments of a bag  
20 such as bag 330 with a perforated divider. Similarly, an applicator and a frangible reservoir  
21 such as frangible reservoir 14 may be held in separate compartments. The advantage of this  
22 arrangement is that the burst pouch or frangible reservoir can be ruptured to enable the  
23 treatment composition to flow into contact with applicator. When a frangible glass reservoir  
24 is used, the perforation prevents glass from contacting the applicator.

25 Fibers such as cotton are not preferred for holding the treatment composition while  
26 agitating the disordered tissue as extended exposure to cotton appears to reduce the efficacy

1 of the methodology. Accordingly, when swab agitation pad 312 is formed from cotton, it is  
2 preferred that the pad not be stored in contact with the treatment composition. The use of  
3 a container such as burst pouch 340 when swab agitation pad 312 is formed from cotton  
4 achieves this objective. Applicators such as a swab may be stored in the same container as  
5 the treatment composition when swab agitation pad 312 is formed from synthetic materials,  
6 naturally occurring fibers which do not reduce the efficacy of the methodology, or fibers such  
7 as cotton which have been appropriately treated. Examples of suitable fibers include those  
8 discussed above in reference to applicator 10. Examples of a single bag or container for  
9 holding a swab are disclosed in U.S. Patent No. 5,704,906 to Fox and U.S. Patent No.  
10 4,952,204 to Korteweg which were both previously referenced. Note that bag 330 and burst  
11 pouch 340 may be formed from any suitable materials and in any suitable manner.

12 Due to the relatively smooth texture of the cotton portion of most conventional  
13 swabs, when such swabs are used it is typically necessary to apply much more pressure than  
14 when an applicator such as applicator 10 or 210 is utilized. Additionally, an applicator such  
15 as applicator 10 is further preferred as applicator 10 enables the treatment composition to be  
16 continuously delivered without requiring rewetting as a swab may. Further, swab agitation  
17 pad 312 holds only small quantities of the treatment composition so it is necessary to rewet  
18 it in order to deliver large volumes of the treatment composition. This prevents swab  
19 agitation pad 312 from rapidly delivering large quantities of the treatment composition.

20 The swab agitation pad may be replaced with a sponge to agitate disordered tissue.  
21 An example of a foam pad or sponge mounted on a stick such as stem 314 is disclosed in  
22 U.S. Patent No. 4,887,994 to Bedford which was previously incorporated. Reference is made  
23 in U.S. Patent No. 4,887,994 at column 2, lines 44-46 to coarse foam pads, such coarse foam  
24 pads are preferred for use as an agitation pad in accordance with the present invention.  
25 Coarse foam pads enable the disordered tissue to be more easily agitated through combined



1 rubbing and application of an appropriate amount of pressure than softer foam pads. The  
2 coarse foam pad may also be utilized with a stick or stem.

3 Like the swab shown at 310, the other embodiments discussed above may be stored  
4 and used in a similar manner. More particularly, the coarse foam pad on a stick, the coarse  
5 foam pad alone, or a towelette may be held in a bag or other sterile container such as is  
6 shown at 330 along with a burst pouch as shown at 340. Additionally, these applicators may  
7 be held in a bag such as bag 330 without a burst pouch 340 in a dry sterile condition for  
8 dipping into a separate reservoir of the treatment composition or the treatment composition  
9 may be held in the bag along with the applicator.

10 Figure 5 is an elevational perspective view of an alternative applicator that includes  
11 a fingertip applicator 410. Fingertip applicator 410 includes an absorbent, agitation pad 412  
12 held on an adhesive surface 414 that the individual being treated or the medical professional  
13 applies to the fingertip. Agitation pad 412 may include an absorbent material for retaining  
14 the treatment composition and it may alternatively contain fixed abrasive elements to assist  
15 in the vigorous irritating of the disordered tissue at the treatment site.

16 Figure 6 is an elevational cross-section view of an alternative applicator that includes  
17 a finger- or digit-container applicator 510. Digit-container applicator 510 includes an  
18 absorbent, agitation pad 512 with a first side 512 that acts as the agitation pad 516, and a  
19 second side 514 that acts at the support 514. The user may rupture the container 516 such  
20 as by tearing a slit 518 and inserting a finger into applicator 510 against second side 514.  
21 Container 516 is a bag like that shown at 330 and may be referred to as what is commonly  
22 called a pillow pouch or package. Container 516 may also contain a burst pouch such as  
23 burst pouch 340. Applicator 510 is, however, preferably pre-moistened by the presence of  
24 treatment composition 522 within container 516. Applicator may also be held in a container  
25 516 in a dry sterile condition for dipping into a separate reservoir of the treatment  
26 composition.

1 First side 512 is made of an absorbent and abrasive material that is substantially  
2 uniform in relation to the size of a disordered tissue site. First side 512 preferably has the  
3 approximate roughness of a conventional gauze bandage or terry cloth. However, first side  
4 512 and/or second side 512 are not necessarily formed from cotton. In fact, as discussed  
5 above, cotton is preferably not used unless it has been appropriately treated not to absorb the  
6 treatment composition, particularly the benzalkonium chloride.

7 Preferably, first side 512 is seamless and devoid of fabric folds etc. Additionally,  
8 where second side 514 is used to interface with a finger, it is a support for first side 512 as  
9 the agitation pad and delivery portion of applicator 510. As a structural explanation of  
10 applicator 510, if applicator were to be turned inside-out, first side 512 would be under  
11 compressive stress and second side would be under tensile stress.

12 Like the other applicators, applicator 510 can have varying sizes depending on its  
13 intended use. For example, if applicator 510 is used to deliver the treatment composition to  
14 a cold sore then it is large enough to enable at least one fingertip into it. However, if  
15 applicator 510 is used to treat the sores caused by shingles on, for example, an individual's  
16 back or other large surface of the body then it may be useful for applicator 510 to be large  
17 enough so that several fingers or even the entire hand can fit inside it like a mit. Such a mit  
18 sized applicator enables the treatment composition to be rapidly delivered to large surface  
19 areas.

20 Figure 7 depicts another embodiment of a system for delivering a treatment  
21 composition to disordered tissue. Like the mit sized version of applicator 510, applicator 610  
22 is very useful for treating large surfaces of the body such as a patient's back. Applicator 610  
23 comprises only four main components: the treatment composition that is contained in a large  
24 frangible ampule 614 or reservoir, the container 616 and pad 612 hold frangible ampule 614  
25 in place.

1 Container 616 has thin-walls at recess 618, the closed end opposite from open  
2 delivery end 617, into which frangible ampule 614 is positioned. When applicator 610 is  
3 ready for use, handle wings 620 are squeezed until they compress the thin sidewalls of  
4 container 616 inward at recess 618 such that pressure is applied to frangible ampule 614 such  
5 that ampule 614 ruptures. The treatment composition is then released and flows into pad  
6 612.

7 Frangible ampule 614 preferably contains a volume of the treatment composition  
8 ranging from about 0.5 ml to about 4 ml. The volume preferably ranges from about 1.5 ml  
9 to about 3 ml and more preferably about 2 ml to about 3 ml.

10 Pad 612 is adhered to the rim of open delivery end 617 of container 616 through any  
11 suitable means such as an adhesive, heat fusion, or a mechanically interlocked configuration.  
12 Pad 612 prevents shards from the rupture ampule from passing through and causing injury.  
13 Once pad 612 is adequately moistened then it can be used to rapidly apply the treatment  
14 composition to large surface areas as shown in Figure 8. Figure 8 depicts the use of  
15 applicator 610 to apply the treatment composition to a patient's chest afflicted with sores  
16 from shingles.

17 Applicator 610 can be used to merely deliver the treatment composition without any  
18 vigorous agitation. Applicator 610 can also be used to apply pressure and/or scrub the  
19 surface area to which the treatment composition is being or has been delivered. Note that  
20 abrasiveness of pad 612 can be varied significantly to achieve varying degrees of ability to  
21 vigorously agitate the disordered tissue. Another example of an applicator that has a  
22 container that also acts as a handle, a glass ampule positioned in the handle and a porous pad  
23 is disclosed in U.S. Patent No. 4,183,684. U.S. Patent No. 4,183,684 is hereby incorporated  
24 by reference. Not only are such applicators are able to deliver the treatment composition to  
25 large surface areas of the body, it is delivered rapidly in large quantities without requiring  
26 rewetting.

1           FIGS. 9-11 depict a towelette being used as an applicator to treat various disordered  
2 tissue. The towelettes depicted at 710 may be a relatively smooth towelette or a relatively  
3 abrasive towelette, the towelettes can also have varying thicknesses. Towelettes are  
4 generally not as useful as other applicators in treating disordered tissue as they require a large  
5 quantity of the treatment composition in order to be wetted and yet deliver only a small  
6 quantity of the treatment composition to the disordered tissue. However, the ability to hold  
7 a greater volume of the treatment composition can be increased by increasing the thickness  
8 of the towelette. Additionally, the towelette can be repeatedly dipped to rewet it. For  
9 example, Figure 9 depicts a user with a finger wrapped in a towelette that is being used to  
10 deliver the treatment composition to a cold sore on the user's lip. The user can then rewet  
11 only the portion of towelette 710 being used to apply pressure to the cold sore.

12           Note that while it is less effective to use a towelette as compared with an applicator  
13 such as applicator 10 since the towelette cannot be used to rapidly deliver a large volume of  
14 the treatment composition it can still serve several functions. As discussed above, a  
15 towelette may be used to preclean the disordered tissue or to deliver an anesthetic.  
16 Precleaning disordered tissue with a towelette, especially an abrasive towelette, may be  
17 useful to awaken the immune response for a synergistic effect once the disordered tissue is  
18 vigorously agitated. The abrasive surface towelette also has the advantage of removing  
19 tissue that is in the process of sloughing off from the disordered tissue site. Such tissue may  
20 provides a hindrance to the inventive method because it restricts penetration of the anti-  
21 infective active agent to living disordered tissue.

22           The towelette may be used to deliver the treatment composition even if it is not as  
23 effective as applicators used to rapidly delivering a large quantity of the treatment  
24 composition. A smooth towelette is generally ineffective in rubbing the disordered tissue as  
25 it has inadequate roughness to agitate the disordered tissue by rubbing it, however, it can be  
26 used to push against the disordered tissue. For example, if towelette 710 is relatively smooth

1 then the user shown in Figure 9 may dab the cold sore with the treatment composition soaked  
2 towelette or the user may apply pressure to the cold sore. Use of a towelette that has a  
3 thickness and smoothness that is comparable to that of ordinary handwipes may be scrunched  
4 in order to better hold the towelette while dabbing the disordered tissue and to concentrate  
5 the moisture held in the towelette. Such a scrunched smooth towelette may result in folds,  
6 so it should not be rubbed against the disordered tissue as it may dig into the disordered  
7 tissue, particularly if it is an open sore. In any event, folds resulting from drawing the  
8 towelette together prevent the towelette from being used to uniformly agitate disordered  
9 tissue through rubbing. If a towelette is be rubbed against the disordered tissue, then it is  
10 preferable to use an abrasive towelette.

11 As indicated above, the abrasive towelettes are distinguished from conventional  
12 towelettes used for cleaning hands, etc. In addition to being too smooth, conventional  
13 towelettes are also typically too thin to hold adequate amounts of moisture while an abrasive  
14 towelette preferably has sufficient thickness to hold adequate amounts of the treatment  
15 composition. Of course, smooth towelettes with increased thickness can also be used. The  
16 abrasive towelettes can also have increased thickness to hold more treatment composition.

17 The towelette fiber may be formed from fibers such as those discussed above in  
18 reference to applicator 10 or any of the other applicators. The towelette may be selected  
19 from existing stock formed from treated natural fibers, synthetic fibers, and untreated natural  
20 fibers. One example of an abrasive towelette is a rough paper towel used in the paper towel  
21 industry or the like. One of ordinary skill in the art may select a towelette that has the  
22 preferred abrasive qualities while maintaining a preferred absorbability in order to convey  
23 the anti-infective active agent to the disordered tissue treatment site.

24 Figure 10 depicts towelette 710 being used in the genital area. An advantage of  
25 using a towelette for delivering the treatment composition in the genital area is that the  
26 towelette is able to conform to the various surface features and it enables the user to deliver

1 the composition with sensitivity to the more sensitive parts in the genital area of the body.  
2 As with the other applicators, the towelette is disposed of after a single use to prevent the  
3 spread of substances contained in the disordered tissue.

4 Figure 11 depicts towelette 710 being used to deliver the treatment composition to  
5 a patient that has sores from shingles on his chest. Since the skin on body parts such as the  
6 chest, arms, the back, etc. are thicker than it is on the lips, use of a towelette is especially less  
7 effective than use of an applicator such as applicator 610. It may however be useful to  
8 preclean the disordered tissue in this manner. Essentially, towelettes are primarily ideal for  
9 areas of the body that have surfaces areas that are not primarily flat or that have irregular  
10 surfaces such as the genital area. The towelette is ideal for these areas as it can access all  
11 areas without causing pain.

12 The towelette may be held in a bag such as the bag shown at 330 which also holds  
13 a burst pouch as shown at 340. Burst pouch 340 holds the treatment composition and is  
14 sized and/or positioned within the bag such that upon bursting it saturates the towelette. The  
15 bag may hold the towelette and the burst pouch in a similar fashion to the designs disclosed  
16 in U.S. Patent No. 5,709,866 to Booras, which was previously referenced. The towelette and  
17 a burst pouch may also be held in separate compartments of a bag such as bag 330 with a  
18 perforated divider. Depending on the material used to form the towelette, it may be  
19 advantageous to either separately store the towelette and the treatment composition, as  
20 discussed above, or to store them together in the same container, especially when the  
21 towelette is formed from synthetic materials. As discussed above, examples of a single bag  
22 or container for holding a towelette are disclosed in U.S. Patent No. 5,704,906 to Fox and  
23 U.S. Patent No. 4,952,204 to Korteweg which were both previously referenced. Towelette  
24 710 may be dipped into a separate reservoir and then used to deliver the treatment  
25 composition.

1           The above embodiments comprise examples of an inventive method and system of  
2 treating disordered tissue. It is preferred not to dip a bare finger into a container of the  
3 treatment composition because oils or other materials contained on the finger may be of  
4 sufficient amount to cause the treatment composition to be rendered ineffective and spread  
5 infection if disordered tissue is infective. Additionally, back contamination of composition  
6 in the container may occur as well as auto-innoculation. The agitation pads 12, 212, 312  
7 412, 612 as well as first side 512 are examples of a delivery and agitation means for  
8 delivering the treatment composition and for agitating the disordered tissue of the patient.  
9 Note that other examples include an abrasive towelette and a coarse foam pad. As discussed  
10 above, a conventional smooth towelette is not an example of a delivery and agitation means  
11 capable of being used to rub the disordered tissue.

12           The container 16 of applicator 10, the finger loop 228 of applicator 210, the stem  
13 314 of applicator 310 or similar applicators, the adhesive surface 414, the second side 514  
14 of applicator 510 and the container 616 of applicator 610 are examples of a means for  
15 supporting the delivery means.

16           A coarse foam pad, pad 212, pad 412, first side 512, pad 612 and abrasive towelette  
17 710 are all examples of delivery and agitation means capable of conforming to the surface  
18 features of the disordered tissue as the corresponding supporting means also conforms to the  
19 surface features. Stated otherwise, the applicator is flexible such that both the delivery and  
20 agitation means as well as the supporting means flex in conformance with the surface  
21 anatomy of the disordered tissue. First side 512 is particularly useful for adapting to the  
22 surface anatomy of the disordered tissue. Pad 612 can also be thick enough to conform to  
23 various surfaces features of the body area being treated.

24           The frangible reservoir 14, container 216, container 516 and frangible ampule 614  
25 are examples of a reservoir means for containing the composition. Additionally, a bottle or  
26 the like that contains treatment composition 22 for use with applicator 310 is another

1 example of a reservoir means for containing the composition. Note that reservoir 14,  
2 container 216, container 516, and ampule 614 however, are configured to be in fluid  
3 communication with the delivery and agitation means. Frangible reservoir 14, burst pouch  
4 340 and frangible ampule 614 are configured to be in fluid communication with the delivery  
5 and agitation means once ruptured. Frangible reservoir 14 and frangible ampule 614 are  
6 further configured to continually deliver the treatment composition to the delivery and  
7 agitation means while the delivery and agitation means is agitating the disordered tissue until  
8 all of the treatment composition has been delivered. Note that one of the primary distinctions  
9 between frangible reservoir 14 as compared with burst pouch 340 is that the frangible  
10 reservoir 14 is located within the container 16. Similarly, frangible ampule 614 is located  
11 within container 616.

12 Container 516 and bag 330 are examples of container means for holding the  
13 applicator. This configuration, as discussed above, enables the applicator to be held in a dry  
14 sterile condition for dipping into a separate reservoir of the treatment composition. As also  
15 indicated above, container 516 and bag 330 can also hold the treatment composition along  
16 with the applicator such that the applicator is premoistened. Accordingly, container 516 and  
17 bag 330 are also examples of container means for holding the applicator and the treatment  
18 composition. As further indicated above, container 516 and bag 330 can also hold the  
19 treatment composition in a pouch along with the applicator. On this basis, container 516 and  
20 bag 330 are also examples of container means for holding the applicator and a reservoir  
21 means.

22 The inventive method of treating disordered tissue and the like includes  
23 impregnating an applicator with the inventive anti-infective composition and contacting the  
24 treatment site with the applicator. Vigorous agitation of the disordered tissue is particularly  
25 useful as the induced physical trauma causes the awakening of the body's immune response  
26 local to the irritation. As such, the immune response and the penetration of the inventive



1 composition into the disordered tissue has the concerted effect of a rapid decline of the  
2 infection.

3 Chemotaxis, the migration of phagocytes such as granular leucocytes and human  
4 leucocyte associated (HLA) antigens to an area of a tissue disorder, is enhanced and assisted  
5 in the present invention by the vigorous agitation of the disordered tissue with the anti-  
6 infective active agent or agents. The combination of the anti-infective active agent,  
7 preferably benzalkonium chloride, with the chemotaxis phenomenon caused by the vigorous  
8 agitation of the disordered tissue, has the surprising effect of a rapid decline of the infectant  
9 such as a virus or a microbe in the disordered tissue. Note that one type of granular  
10 leucocyte, the neutrophil, has the ability to activate defenses which are amino acids that  
11 exhibit a broad range of antibiotic activity against bacteria, fungi, and viruses. Consequently  
12 the synergistic effect of vigorous agitation is rapid delivery and the awakening of the immune  
13 response. The neutrophil, if activated is therefore useful to treat disordered tissue according  
14 to the present invention where bacteria, fungi, or virus infections occur. Further, agitation  
15 causes fluids to concentrate in the area of the disordered tissue which further enables the  
16 active agent to move as needed in order to penetrate effectively.

17 Other immune responses may occur with the vigorous agitation of the disordered  
18 tissue site by the inventive method, and the inventors do not wish to be bound to any single  
19 theory that may explain the surprising efficacy of the inventive method and system.

### 20 TESTS AND EXAMPLES

21 The following tests and examples are provided as illustrative of the inventive  
22 method and system. These tests and examples are not intended to be limiting of the  
23 invention. The tests and examples produce clinically discernable improvement of disordered  
24 tissue. By "clinically discernable improvement of disordered tissue," it is understood that  
25 various testing methods may be used to quantify improvement of disordered tissue. One  
26

1 example of clinically discernable improvement of disordered tissue include arresting the  
2 normal progression of a tissue disorder such as a cold sore. Another example of clinically  
3 discernable improvement of disordered tissue is healing of a tissue disorder at a faster rate  
4 than was observed before in a recurrent disorder such as a cold sore. Another example of  
5 clinically discernable improvement of disordered tissue is an arrest of pain usually associated  
6 with the progression of a tissue disorder such as a cold sore. Another example of clinically  
7 discernable improvement of disordered tissue is the permanent deactivation of a recurrent  
8 tissue disorder site after the inventive method is applied to a disordered tissue site.

9 Other ways to evaluate the progression of the cold sore healing process include  
10 measuring the size of the cold sore and also the degree of inflammation thereof. One such  
11 method of evaluation is colorimetry of inflamed tissue that creates a color scale that has  
12 apparently healthy tissue of the patient as the baseline, and ranks the inflamed color with  
13 some external standard or that nominalizes the inflamed tissue such as being at a nominal red  
14 scale of 10. A "nominal red scale" is defined as assigning the tissue color a nominal 10; a  
15 nominal zero being undisordered tissue of the same type for the specific patient. Clinically  
16 discernable improvement of inflamed tissue is defined as reducing in the nominal red scale  
17 within about 24 hours by as much as about two or more on the nominal red scale of 10. With  
18 a disordered tissue having substantially no clinically discernable improvement of disordered  
19 tissue, a red scale decrease of below about one or less within 24 hours is observed.

20 Another method is the assay of eosinophils and other immune response substances  
21 in the inflamed area before and after the inventive method of treatment. Where the presence  
22 of eosinophils and the like increases by more than about 10% within about one hour of the  
23 inventive method of treatment, as opposed to less than about 10% increase in eosinophils and  
24 the like with a control cold sore, a clinically discernable improvement has occurred.

25 The clinical tests provided hereinbelow were performed with a treatment  
26 composition which included benzalkonium chloride. The carrier was aqueous isopropyl

1 alcohol (70% by volume isopropyl alcohol). The treatment composition was prepared with  
2 about one part benzalkonium chloride to about 750 parts carrier. More particularly, 5 drops  
3 of benzalkonium chloride having a concentration of about 17% in isopropyl alcohol were  
4 added for each ounce of the carrier. The result was a treatment composition containing about  
5 0.133% benzalkonium chloride by weight of the treatment composition. Although additives  
6 and other constituents may be combined with the mixture as set forth above these particular  
7 test treatment compositions did not include any additives.

8 As discussed above, the methodology in the examples includes vigorously applying  
9 the composition to the disordered tissue and removing the superficial lipids by the carrier.  
10 The carrier also is useful for the penetration of the disordered cells at the tissue disorder site.  
11 Either following or simultaneously with the penetration of disordered cells with the  
12 composition at the tissue disorder site, vigorous agitation of the tissue with the composition  
13 is carried out under conditions to increase the flow of intercellular fluid to the tissue at the  
14 tissue disorder site. This enables the active agent greater ease of transportation at the site to  
15 better penetrate.

## 17 CLINICAL TESTING IN HUMANS

### 18 Clinical Test 1

19 A male was diagnosed with several vesicles beginning to coalesce on the lip.  
20 Treatment was initiated immediately. After about 1 day, it was observed that the vesicles  
21 had not coalesced further and that progression of the cold sore through its normal stages was  
22 arrested. After about two days, scab tissue was observed to be sloughing off. After about  
23 seven days, no sign was left of the disordered tissue. The patient observed that for previous  
24 eruptions the complete healing of this cold sore at this site took from about two to three  
25 weeks.

1                   **Clinical Test 2**

2                   A male was diagnosed with a cold sore erupting below the corner of the mouth. The  
3                   usual tingling and tightening sensation that occurs with a cold sore onset was observed by  
4                   the patient. The inventive composition and method was applied to the patient according to  
5                   the inventive method. Immediately upon application, the usual tingling and tightening  
6                   sensation was not noticed. After about two days, no visible sign of a cold sore was  
7                   observable.  
8

9                   **Clinical Test 3**

10                  A male with a history of cold sores ranging in a size from about 1.5 cm to about  
11                  2.5 cm in diameter was treated immediately upon sensing the tingling and tightening of an  
12                  oncoming cold sore. A numbing sensation was immediately noticed and the pain was gone.  
13                  After about 3 days, the cold sore had begun to heal.  
14

15                  **Clinical Test 4**

16                  A female was diagnosed with pustules and vistules upon the lower lip. The  
17                  inventive composition was applied to the patient according to the inventive method, and pain  
18                  was gone as soon as the application of the inventive composition was done. Instead of the  
19                  normal weeping and scabbing the patient was used to, the cold sore healed without weeping,  
20                  and pain was minimal in comparison to previous experiences.  
21

22                  **Clinical Test 5**

23                  A female had a disordered tissue eruption upon a digit with about 7 vistules in the  
24                  pre-eruption stage. The blistering typical of this type of tissue disorder began to fade  
25                  immediately after application of the inventive composition. A small amount of scaling was

1 observed after about 2 weeks. The patient observed that the normal course of an eruption  
2 and healing at this cold sore site was shortened by the inventive composition and method.

3  
4 **Clinical Test 6**

5 A female was diagnosed with a cold sore taking up about one-half of the area of the  
6 lower lip. The cold sore had multiple lesions. The inventive composition was vigorously  
7 applied to the cold sore. Pain was immediately relieved and weeping was immediately  
8 arrested from the cold sore.

9  
10 **Clinical Test 7**

11 A female observed tingling and tightening upon the inside of her lip in the evening  
12 and observed one small pustule and three to four vistules at the time of treatment the next  
13 morning. The inventive composition was applied by vigorous rubbing with a cotton swab.  
14 A second treatment was carried out that evening, and a third treatment was carried out the  
15 following morning. The pain was observed to be relieved fairly quickly upon the first  
16 treatment. The patient observed that the inventive composition and method worked at least  
17 as well as her usual Zovirax® prescription, manufactured by Glaxo Wellcome Inc. of  
18 Research Triangle Park, North Carolina. The following advantages of the inventive  
19 composition and method were observed in comparison. One advantage was that fewer  
20 applications were required. Additionally, no unpleasant tasting ointment remains upon the  
21 lip during the treatment time.

22  
23 **Clinical Test 8**

24 A female with a cold sore history including at least one eruption per month was  
25 diagnosed with some yellow scabbing present upon a cold sore site. After vigorous irritation

1 of the disordered tissue with the inventive composition, the patient observed that pain was  
2 completely gone after about seven hours.

3  
4 **Clinical Test 9**

5 A male was diagnosed with a cold sore upon the lower lip. The inventive  
6 composition was applied by rubbing. The cold sore was observed to be healed after two  
7 days.

8  
9 **Clinical Test 10**

10 A male was diagnosed with a number of cold sores at the corner of the mouth and  
11 above the lip. Prior to vesicular eruption, the usual pain that precedes the eruption of a cold  
12 sore was observed about 24 hours previously. The inventive composition was applied by  
13 rubbing. Growth of the disordered tissue was immediately arrested and the tissue appeared  
14 to have cleared in three days following the treatment.

15  
16 **Clinical Test 11**

17 A female diagnosed with a cold sore upon the chin about half way between the base  
18 of the chin and the lower lip. The inventive composition was applied with rubbing. The cold  
19 sore was observed to have healed within about two days.

20  
21 **Clinical Test 12**

22 A six year old female was diagnosed with an open cold sore upon the lower lip. The  
23 inventive composition was applied by vigorous rubbing. The cold sore was barely  
24 observable in about three days.

25

1                   **Clinical Test 13**

2                   A male was diagnosed with a cold sore upon the lower lip. The inventive  
3 composition was applied by vigorous rubbing. The progression of the cold sore was arrested  
4 and pain was stopped within a few minutes.  
5

6                   **Clinical Test 14**

7                   A female was diagnosed with a cold sore at the corner of the mouth that would crack  
8 when the mouth was opened. The inventive composition was applied by vigorous rubbing.  
9 Within about two days, the cold sore was observed to be completely healed. The patient  
10 observed that cold sores in the corner of the mouth of this type usually took at least 7 to 10  
11 days to heal.  
12

13                   **Clinical Test 15**

14                   A three-year old male was diagnosed with a cold sore upon the lip. The inventive  
15 composition was applied by vigorous rubbing. It was observed that progression of the cold  
16 sore was immediately arrested and that the cold sore did not form at that site again. The  
17 patient had about six sites that erupted upon the lips frequently, and no treated site re-erupted  
18 after treatment.  
19

20                   **Clinical Test 16**

21                   A four-year old male with a history of about 25 oral cold sores was treated by  
22 vigorous agitation of the disordered tissue upon a re-eruption of each untreated cold sore.  
23 Pain was observed to cease immediately upon treatment. Additionally, the cold sore did not  
24 erupt again at any of the specific treatment sites even after a year.  
25

1           **Clinical Test 17**

2           A male was diagnosed with a cold sore below the corner of the lower lip. The  
3           inventive composition was applied by vigorous rubbing. Immediately upon application, the  
4           tingling sensation that accompanied the cold sore was gone. The next morning the cold sore  
5           had closed and was scabbed and healing. Within two days of the application, the cold sore  
6           was completely healed. The patient observed that normal healing time, before the inventive  
7           treatment, took about two weeks.

8  
9           **Clinical Test 18**

10          A male was diagnosed with a cold sore in the vistial stage upon the lower lip. The  
11          inventive composition was applied by vigorous rubbing. The cold sore was observed not to  
12          progress beyond the vistial stage. Healing occurred without pain and throbbing. The cold  
13          sore was totally healed within seven days.

14  
15          **Clinical Test 19**

16          A female was diagnosed with two cold sores upon the lower lip. The inventive  
17          composition was applied by vigorous rubbing between about 30 and about 60 seconds. No  
18          pain was felt after the vigorous rubbing. Two days later, one of the cold sores was gone and  
19          the other one had a slight scab that was also gone after three more days.

20  
21          **Clinical Test 20**

22          A female was diagnosed with a cold sore that was about 2 cm across and generally  
23          round in shape, below one corner of the lower lip. The inventive composition was applied  
24          by vigorous rubbing. The patient described the cold sore to be burning and weeping. Within  
25          about one minute of treatment, the burning had stopped. Within hours, the weeping stopped



1 and a normal or non-cold sore scab appeared. Within days, the cold sore was gone and  
2 healed. No re-occurrence of the cold sore was observed.

3  
4 **Clinical Test 21**

5 A male was diagnosed with an extremely swollen, red and weeping cold sore above  
6 one eye. The inventive composition was applied by vigorous rubbing to the cold sore. The  
7 swelling and redness were reduced within minutes of the treatment. By the next morning,  
8 the cold sore appeared to be a normal or non-cold sore scab. Complete healing was observed  
9 after about four days.

10  
11 **Clinical Test 22**

12 A female was diagnosed with a canker or ulcer. The inventive composition was  
13 applied by vigorous rubbing until blood was seen on the cotton swab. The patient observed  
14 that the canker was gone after only about two or three days. When the patient was re-  
15 examined one week after the treatment, there was no sign of the canker.

16  
17 **Clinical Test 23**

18 A male was diagnosed with shingles in two eruptions; one upon the face over the  
19 cheekbone and the other upon the back of the neck. The inventive composition was applied  
20 by vigorous rubbing to the eruption upon the face. Immediate reduction in discomfort was  
21 observed. The redness also immediately began to fade. The patient used shaving soap the  
22 same day following treatment and observed that the eruption on the face was returning. A  
23 second treatment was repeated in the same manner and progress was again arrested. The  
24 treatment site was not contacted the second time with any soap. The eruption on the face  
25 healed completely while the eruption on the back of the neck remained even after about four

1 weeks. Treatment was carried out on the eruption on the back of the neck and the eruption  
2 was healed in a few days.

3  
4 **Clinical Test 24**

5 A female was diagnosed with a rash of shingles across the midsection above and at  
6 the naval. The inventive composition was applied by extensive and vigorous rubbing for  
7 about 20 minutes. The progression of the rash was immediately arrested and no new  
8 outbreaks were observed. The rash had been growing from small spots into large sores.

9  
10 **Clinical Test 25**

11 A number of patients with primary eruption cases were treated by the inventive  
12 method. It was observed that in each patient, there was no reoccurrence of cold sores, as is  
13 typical with untreated primary occurrences.

14  
15 **Clinical Test 26**

16 An individual was diagnosed with what appeared to be a spider bite upon the lower  
17 calf area of the leg from a Brown Recluse. A "bullseye" discoloration was observed at the  
18 bite location with a brown-red middle region and a red circumferential region. The entire  
19 area affected by the venom appeared to be about eight to about nine centimeters in diameter.  
20 The inventive composition was applied by vigorous rubbing. After an overnight wait  
21 following treatment, the discoloration was not observable. A scab that formed at the center  
22 of the bite, fell off after about three days.

23 Herpes types I and II infect all areas of the body because of life style changes.  
24 Genital herpes is known to be caused by any one of herpes 1 and 2. Herpes type 1 was  
25 previously localized on the lips whereas herpes type 2 was found in the genital area. Herpes  
26 types 1 and 2 infect nowadays the lip and genital areas and they also infect the skin through

1 scratches or other injuries. These infected areas include the eyes, nose, any mucous  
2 membranes, anal tissue, mouth and throat tissues, pubic area tissue, anal area, and portions  
3 of skin that are scratched, pricked or otherwise injured. Treatment according to the present  
4 invention for any herpes skin lesion in any area has shown the same surprising reduction of  
5 pain, the stopping of the infection and quick healing. Surprisingly another herpes infection,  
6 chicken pox sores respond to treatment according to the present invention by stopping the  
7 intense itching, which in turn stops the scratching with its sores and scaring. The progression  
8 of the pox stopped and healing was surprisingly rapid with this treatment.

9 The number and severity of any of the Herpes types I and II outbreaks that are treated  
10 quickly and aggressively according to the present invention are reduced or stopped. It is  
11 believed that the nerve pathways that enable the re-infection are affected in such a way that  
12 the re-infection no longer occurs.

#### 13 14 Clinical Test 27

15 Young woman presented with Herpes in the genital area, apparently infected by non-  
16 sexual means. The infection occurred when this individual was 20, it was diagnosed as  
17 herpes by a physician and treated with acyclovir. Normal recurrence presented and it was  
18 treated aggressively according to the present invention, resulting in surprising healing of the  
19 infection. The recurrence lesions surprisingly stopped and this individual has been lesion  
20 free for one and a half years after the aggressive treatment of the lesions that had appeared.

#### 21 22 Clinical Test 28

23 A woman of about 45 had a history of herpetic lesions in the genital area that  
24 recurred almost every month at menstruation time. This individual experienced pain relief  
25 and quick healing after aggressive treatment according to the present invention. The time  
26 between recurrences has surprisingly decreased and this individual has been lesion-free for

over three months. The lesion sites are being eliminated and no return of such lesions is being observed.

**Clinical Test 29**

A male diagnosed with a cold sore in the corner of the eye lid, a lesion that subsequently progressed onto the white of the eye. Careful treatment according to the present invention stopped the progression of the lesion, and healed it without scarring. Lesions of this type that extend to the cornea can lead to blindness.

**Clinical Test 30**

A female under treatment with interferon for leukemia had constant recurrence of cold sores on her lips and inside her mouth; she was constantly afflicted by lesions in progress. At the time of treatment according to this invention, she had one cold sore lesion healing on her lip and a count of about 30 vesicles forming inside her lip and mouth. Treatment according to the present invention stopped the pain and all the vesicles healed without producing lesions. No new lesion developed for a nine-month period after the treatment according to this invention.

**Clinical Test 31**

A male had a history of cold sores developing about six times a year. The lesions would break out at one of five places on the lips. Treatment according to the present invention lead to the reduction of lesions and also to an increase in the time between lesion recurrence. It was observed that the more quickly the lesions were treated upon noticing their onset, the more effective was the reduction of both the lesions and the number of affected sites. All the lesion sites have been free of cold sores for over one year, and some sites have not had lesions for more than two years.

1                   **Clinical Test 32**

2                   A 56 year old woman underwent a bone marrow transplant resulting in an  
3 immunosuppressed condition. She subsequently contracted chicken pox and experienced  
4 classic chicken pox lesions over approximately 60% of her body from just above the genital  
5 area and covering her trunk, arms, and head. There were multiple pox manifestations of  
6 which 2 were scratched open. There was intense itching and pain associated with the pox.  
7 The condition was diagnosed as chicken pox (Herpes Varicella-Zoster Virus) by a physician.  
8 A treatment according to this invention was applied by using the rubbing action described  
9 herein on each pox or lesion for approximately 10 seconds per lesion. The pox  
10 manifestations were too numerous to count, but were estimated to exceed one hundred.  
11 Treatment of such extensive manifestations took approximately one hour. Following  
12 treatment, pain and itching symptomatically abated in about 10 minutes. There was no  
13 further progression of any of the treated sores. The condition fully abated with a return to  
14 intact skin with normal appearance and with no pain or itching within two days. There have  
15 been no recurrences since the time the treatment according to the present invention was  
16 administered.

17  
18                   **Clinical Test 33**

19                   A female, age 45, with clinical history of recurrent Herpes Zoster (HZV), commonly  
20 known as shingles, experienced a recurrent outbreak after a stressful week at work and a  
21 weekend in the sun. This subject had her first episode with HZV about one year prior to the  
22 presently described outbreak. She was diagnosed by her physician and given a prescription  
23 for Zovirax. She has had three episodes of HZV outbreaks since then that were not treated  
24 with Zovirax. The lesions included all the classic stages for this disease, including weeping,  
25 but the outbreaks caused small lesions in rather small numbers, such as three or four in each  
26 episode. Each of these recurring episodes lasted at least three or four weeks. Treatment

1 according to this invention was applied to a recurrence that was in the beginning of the third  
2 day and had progressed from prodromal "tingle", through papule (raised bump) to vesicle,  
3 and to ulcerated vesicles. Ulceration may have been exacerbated by inadvertent scratching  
4 of the lesions. This is a tendency that is often experienced by individuals with this type of  
5 lesions, despite their best efforts not to scratch the itching areas of their bodies. This  
6 individual reported that the pain was localized at each lesion site, but that the experienced  
7 overall discomfort had made it difficult to sleep the night before. Approximately 35 distinct  
8 lesions were displayed by this individual at the time of this treatment, and these lesions were  
9 located in the chest area and covered approximately one fourth of the upper chest area,  
10 spreading up onto her shoulders. The lesions varied in size from about 3 mm x 5 mm to the  
11 largest, which was a series of lesions that had joined together to form a lesion area of about  
12 18 mm x 25 mm. The subject reported that this was the worst episode of HZV that she had  
13 ever experienced in all aspects: It was the most painful, covered the largest area, and it was  
14 the most bothersome.

15 Prior to treatment according to the present invention at 10 am, the lesions were  
16 consistent with herpes lesions, but epithelial damage was still limited, probably due to the  
17 early stage of the disease progression. A solution according to the present invention was  
18 rubbed onto each sore site in accordance with the rubbing action described herein. Following  
19 treatment, the area was rubbed using bulk solution. This subject reported a gradual loss of  
20 pain, itching, and burning during the day of treatment, and her sleep that night was trouble-  
21 free. All the pain, itching and burning had subsided the next day, and the lesions were  
22 beginning to scab. Four days following the treatment according to the present invention, all  
23 but a few small scabs had fallen off. No other symptoms were present about 102 hours  
24 following the treatment. Furthermore, no adverse events were experienced.

25

### Comparative Clinical Test 1

A female was diagnosed with a cold sore above the upper corner of the upper lip. The inventive composition was applied but only slight rubbing occurred. Soap was used on the cold sore treatment site that evening. Although the cold sore formed a scab after about two days, a new cold sore erupted at that time above the existing scab and spread itself into the scab.

## CLINICAL TESTING OF VACCINA VIRUS IN MICE

### Study QAA-1

This study examined the effects of topical treatment with a benzalkonium compound on skin lesion development and mortality in immunosuppressed hairless mice infected with the vaccinia virus (Western Reserve Strain). Complications may arise from the vaccination of immunosuppressed individuals with the smallpox vaccine prepared from an attenuated vaccinia virus. The National Institute of Health is seeking compounds that will treat such a condition. A vaccinia skin infection model in immunosuppressed hairless mice was utilized to study drug effects using a topical benzalkonium compound preparation. Immunosuppressed mice (due to cyclophosphamide treatment) develop a progressive vaccinia infection characterized by spreading of the primary lesions to peripheral sites. The virus eventually causes the mice to get sick and die, suggesting internal spread. This probable cause of death has not yet been verified, however.

### Materials and Methods

*Animals:* Male 6-week-old (about 28-30 g) specific pathogen-free hairless mice were obtained from Simonsen Labs, Gilroy, CA. They were quarantined 48 hours prior to use and maintained on Wayne Lab Blox and tap water in the AAALAC-accredited

1 Laboratory Animal Research Center of Utah State University. The mice were individually  
2 housed because they are prone to fight and bite each other, which could spread the infection.

3 *Virus:* Vaccinia virus (WR strain) was purchased from the American Type Culture  
4 Collection, Manassas, VA. The virus was propagated in African green monkey kidney (MA-  
5 104) cells for use in these studies.

6 *Compound:* The benzalkonium compound preparation was provided by Quadex  
7 Labs Inc. of Salt Lake City, Utah. It was pre-formulated by the company and placed in  
8 ampules. The placebo vehicle was provided by the company in a similar container. The  
9 ampules were labeled simply A or B. The investigators did not know which one contained  
10 the active ingredient until the end of the study.

11 *Experiment Design:* Mice were anesthetized with Ketamine (100 mg/kg) by  
12 intraperitoneal (i.p.) injection. They were scratched in the hip and shoulder areas on one side  
13 of the body. The area of each scratched area was about 25 mm<sup>2</sup> (5 mm x 5 mm). A 25 µl  
14 volume of virus (containing about 5 x 10<sup>5</sup> plaque forming virus units) was placed on each  
15 wound site and remained there while the animals rested under the influence of the anesthesia.  
16 Topical treatments began 24 hours after infection and were given twice a day for three days.  
17 Immunosuppression was accomplished by treating the mice i.p. every 4 days with  
18 cyclophosphamide (100 mg/kg/day) starting 1 day before virus challenge. Note that without  
19 immunosuppression, virus lesions do not develop beyond the primary wound site, and the  
20 primary wound site does not develop into a severe lesion.

21 Lesions were evaluated by giving them a subjective score ranging from 0 (no lesion)  
22 to 4 (maximum, which involved areas away from the primary site of infection). Skin of mice  
23 that died from the infection were extensively affected. In some animals, virus was present  
24 on the tail, ears, head, lips, and/or paws in addition to the back. Arbitrary lesion scores of  
25 4 were assigned to dead animals each scoring day for the remainder of the study. Lesion  
26 areas were determined by measurement in square millimeters (length x width). The primary



1 lesion and satellite lesion areas were determined. Arbitrary lesion areas of 100 were assigned  
2 to dead animals each scoring for the remainder of the study.

3 *Statistical Evaluation:* The two-tailed Fisher exact test was used to evaluate  
4 survivor number increases (however, there were no survivors). The two-tailed Mann-  
5 Whitney U-test was used to analyze differences in the mean day of death, lesion score  
6 reductions, and lesion area reductions.

### 8 Results and Discussion

9 The tabular results of this experiment are summarized in Table 1 set forth below.  
10 No protection from death was afforded by treatment with the benzalkonium compound, as  
11 the mice were all immunosuppressed. However, a 4-day increase in the mean day of death  
12 was evident in the treated group compared to placebo controls. Mean lesion scores and  
13 lesion areas were determined during the infection. Treatment with the benzalkonium  
14 compound caused statistically significant reductions in lesion scores and lesion areas on days  
15 8 and 10 of the infection. According to the results tabulated in Table 1, death, lesion scores,  
16 and lesion areas were delayed by treatment with the benzalkonium compound.

17 In this infection model, because of the immunosuppression of the test mice, the virus  
18 will persist indefinitely and propagate unless completely eradicated. The results indicate that  
19 the active treatment reduced virus in the mice for a period of time but did not eradicate it.  
20 Thus, the virus was able to replicate and spread after cessation of treatment. The overall  
21 results of the study are encouraging and suggest that continued treatment beyond three days  
22 may result in increased benefit to the infected host.

### 24 Table 1

25 Effects of topical treatment with a benzalkonium compound on a lethal vaccina virus  
26 (WR strain) skin infection in immunosuppressed (with cyclophosphamide)<sup>a</sup> hairless mice.

Compound	Survivors/ Total	Mean Day of Death <sup>b</sup> ±SD	Lesion Score/Lesion Area (mm) on Day Post-Infection ± SD				
			3 <sup>c</sup>	6	8	10	12
Benzalkonium Compound	0/10	11.3±1.1***	0.6±0.1 8±2.0	1.4±0.3 25±6.6	1.6±0.5*** 37±18***	3.4±0.7* 85±29**	4.0±0.0 100±100
Placebo	0.10	7.4	0.6±0.2 9±4.7	1.6±0.9 33±25	3.6±0.9 88±24	3.9±0.2 99±8	4.0±0.0 100±100

<sup>a</sup>The 100 mg/kg/day dose was given by intraperitoneal injection on days 1, 3, 7 and 11 of the infection.

<sup>b</sup>Of mice that died prior to day 21.

<sup>c</sup>Day after virus exposure.

\*P<0.05, \*\*P<0.01, \*\*\*P<0.001. All other comparisons were not statistically significant (P>0.05).

### Conclusions

Treatment of vaccinia virus skin infections in immunosuppressed hairless mice with a benzalkonium compound twice a day for three days starting 24 hours after infection significantly delayed disease progression.

### Study QAA-3

This study examined the effects of topical treatment with benzalkonium chloride on skin lesion development and mortality in immunosuppressed hairless mice infected with the vaccinia virus (Western Reserve Strain) when two treatments per day were given. In the first study with benzalkonium chloride formulated in isopropanol (Study QAA-1), treatment twice a day for three days starting 24 hours after virus exposure resulted in a four day delay in death, and in a corresponding delay in development of lesions in vaccinia virus-infected, cyclophosphamide-immunosuppressed mice.

A second study was conducted in which more vigorous rubbing in of the medication was done, and the treatment was continued until death. In the second study the treatment appeared to provide no benefit to the mice in terms of survival or suppressing lesion severity.

1 The vigorous application of the medication may have agitated the wounds and contributed  
2 to disease progression.

3 A third experiment was then proposed in which topical application would be  
4 conducted in a more gentle fashion than in the second study, *i.e.*, by dabbing on the  
5 medication as in Study QAA-1. Three and six day treatment regimens were proposed in order  
6 to determine if longer treatment would enhance the efficacy of the compound. Additionally,  
7 it was decided to use water as the control rather than isopropanol, since isopropanol could  
8 inactivate virus and exhibit an antiviral effect. Thus, water would not represent a true  
9 placebo control. Benzalkonium chloride was still formulated in isopropanol for treatment,  
10 however. This study (QAA-3) incorporates these changes from the previous experiments.

#### 11 12 Materials and Methods

13 *Animals:* Male 7-9 week old (about 28-30 g) specific pathogen-free hairless mice  
14 were obtained from Simonsen Labs, Gilroy, CA. They were quarantined 48 hours prior to  
15 use and maintained on Wayne Lab Blox and tap water in the AAALAC-accredited  
16 Laboratory Animal Research Center of Utah State University. The mice were individually  
17 housed because they were prone to fight and bite each other, which could spread the  
18 infection.

19 *Virus:* Vaccinia virus (WR strain) was purchased from the American Type Culture  
20 Collection, Manassas, VA. The virus was propagated in African green monkey kidney  
21 (MA-104) cells for use in these studies.

22 *Compound:* The benzalkonium chloride preparation and water control were  
23 provided by Quadex Labs, Inc. of Salt Lake City, Utah. The compounds were pre-formulated  
24 in ampoules. The ampoules were labeled simply 1, 3, 5 or 7. The investigators did not know  
25 which one contained the benzalkonium chloride ingredient until the end of the study.

1       *Experiment Design:* Mice were anesthetized with Ketamine (100 mg/kg) by  
2 intraperitoneal (i.p.) injection. They were scratched in the hip and shoulder areas on one side  
3 of the body. The area of each scratched area was about 25 mm<sup>2</sup> (5 mm x 5 mm). A 25 µl  
4 volume of virus (containing about 3.2 x 10<sup>5</sup> plaque forming virus units) was placed on each  
5 wound site and remained there while the animals rested under the influence of the anesthesia.  
6 The infecting virus titer differed slightly from the 5 x 10<sup>5</sup> plaque forming units per lesion  
7 used in Study QAA-1, but was the same as in the second study. This was done so that the  
8 infection proceeded slowly, allowing more days of lesion scoring before the mice died. The  
9 virus pool was the same as used in the second study. Thus, the present study was similar to  
10 the second study except for the days of treatment, number of treatments per day, and the  
11 more gentle treatment method used.

12       Topical treatments began 24 hours after infection and were given twice a day (at 9  
13 a.m. and 5 p.m.) for 3 or 6 days. The liquids were dabbed on as was done in Study QAA-1.  
14 This differed from the second study in which the solutions were rubbed on vigorously.

15       Immunosuppression was accomplished by treating the mice i.p. every 4 days with  
16 cyclophosphamide (100 mg/kg/ day) starting 1 day before virus challenge. Without  
17 immunosuppression, virus lesions do not develop beyond the primary wound site, and the  
18 primary wound site does not develop into a severe lesion.

19       Lesions were evaluated by giving them a subjective score ranging from 0 (no lesion)  
20 to 4 (maximum, which involved areas away from the primary site of infection). Skin of mice  
21 that died from the infection was extensively affected. In some animals, virus lesions were  
22 present on the tail, ears, head, lips, and/or paws in addition to the back. Arbitrary lesion  
23 scores of 4 were assigned to dead animals on each scoring day for the remainder of the study.  
24 Lesion areas were determined by measurement in square millimeters (length x width). The  
25 primary lesion and satellite lesion areas were determined. Arbitrary lesion areas of 100 were  
26 assigned to dead animals on each scoring for the remainder of the study.

1           *Statistical Evaluation:* The two-tailed Fisher exact test was used to evaluate  
2 survivor number increases (however, there were no survivors). The two-tailed  
3 Mann-Whitney U-test was used to analyze differences in the mean day of death, lesion score  
4 reductions, and lesion area reductions.

5  
6           Results and Discussion

7           The mortality results of this experiment are summarized in Table 2 set forth below.  
8 No protection from death was afforded by treatment with benzalkonium chloride nor the  
9 water control, as the mice were all immunosuppressed. The mean day of death in the two  
10 benzalkonium chloride groups were longer than those respective groups treated with water,  
11 but the results were not statistically significant. Originally the plan was to have 10 mice per  
12 group. One mouse died during quarantine before the start of the experiment. The second  
13 mouse was found dead on the day of infection. These animals were not included in the  
14 results.

15           Treatment with benzalkonium chloride caused significant reductions in lesion scores  
16 and lesion areas on days 7, 9, and/ or 11 of the infection compared to water tabulated in  
17 Tables 3 and 4 below). Overall, the 6-day treatment results may have been slightly better  
18 than the 3-day results, but if compared on a statistical basis there would be no differences.

19           Mice lived long enough to develop rather severe lesions, some of which greatly  
20 exceeded the 100 mm<sup>2</sup> areas that more typically occur near death. Lesion areas  $\geq 200$  mm<sup>2</sup>  
21 were seen in some mice. Since dead mice were arbitrarily assigned a score of 100, this  
22 means that mice dying with high scores would have their scores reduced thereafter on  
23 subsequent scoring days. More mice were alive in the benzalkonium chloride treated group  
24 on day 16 than in the water group (for 3-day treatment results), and many of these mice had  
25 lesion scores well above 100. This explains why the day 16 lesion scores differed between

the benzalkonium chloride and water groups (Table 3). A similar pattern occurred in the 6-day treatment groups on day 16 (Table 4).

Groups of mice in the second and third (QAA-3) studies lived longer than the mice of the first study (QAA-1), particularly the vehicle control groups. This may reflect the fact that the infecting virus titer was slightly less, or may also be due to changing of the infecting virus pool. These longer lasting infections (until death occurred) allowed for more days of lesion scoring.

Table 2

Effects of topical treatment with benzalkonium chloride and water control on survival of mice during a lethal vaccina virus (WR strain) skin infection in immunosuppressed (with cyclophosphamide)<sup>a</sup> hairless mice.

Compound	Days of Treatment	Survivors/Total	Mean Day of Death <sup>b</sup> ± SD
Benzalkonium Chloride	3	0/10	14.7 ± 1.6
Water Control	3	0/10	13.3 ± 1.3
Benzalkonium Chloride	6	0/10	15.4 ± 2.2
Water Control	6	0/10	4.6 ± 2.4

<sup>a</sup>The 100 mg/kg/day dose was given by intraperitoneal injection on days 1, 3, 7, 11 and 15 of the infection.

<sup>b</sup>Of mice that died prior to day 21.

No comparisons were not statistically significant (P>0.05).

Table 3

Effects of topical treatment with benzalkonium chloride and vehicle control on vaccina virus (WR strain) skin lesion scores and lesion areas on the backs of hairless mice that were

immunosuppressed with cyclophosphamide.<sup>a</sup> Topical treatments were given twice a day for 3 days starting 24 hours after infection.

Day Post-Infection	Mean Lesion Score $\pm$ SD		Mean Lesion Area $\pm$ SD	
	Water Control	Benzalkonium Chloride	Water Control	Benzalkonium Chloride
3	0.51 $\pm$ 0.14	0.47 $\pm$ 0.12	5.8 $\pm$ 2.2	5.3 $\pm$ 2.2
5	0.61 $\pm$ 0.12	0.57 $\pm$ 0.17	9.7 $\pm$ 3.2	8.3 $\pm$ 3.2
7	1.51 $\pm$ 0.36	1.14 $\pm$ 0.38**	30.4 $\pm$ 6.3	23.3 $\pm$ 7.4**
9	1.84 $\pm$ 0.44	1.43 $\pm$ 0.59*	37.3 $\pm$ 12.7	28.6 $\pm$ 12.8*
11	3.17 $\pm$ 0.69	2.59 $\pm$ 0.96	81.1 $\pm$ 12.7	65.7 $\pm$ 38.0
13	3.88 $\pm$ 0.36	3.52 $\pm$ 0.64	97.1 $\pm$ 11.5	94.2 $\pm$ 26.4
16	3.94 $\pm$ 0.16	3.88 $\pm$ 0.32	106.9 $\pm$ 20.7	130.0 $\pm$ 48.9

<sup>a</sup>The 100 mg/kg/day dose was given by intraperitoneal injection on days 1, 3, 7 and 11 of the infection.

\*P<0.05, \*\*P<0.01

Table 4

Effects of topical treatment with benzalkonium chloride and vehicle control on vaccinia virus (WR strain) skin lesion scores and lesion areas on the backs of hairless mice that were immunosuppressed with cyclophosphamide.<sup>a</sup> Topical treatments were given twice a day for 6 days starting 24 hours after infection.

Day Post-Infection	Mean Lesion Score $\pm$ SD		Mean Lesion Area $\pm$ SD	
	Water Control	Benzalkonium Chloride	Water Control	Benzalkonium Chloride
3	0.49 $\pm$ 0.09	0.47 $\pm$ 0.10	5.2 $\pm$ 1.8	5.0 $\pm$ 1.4
5	0.58 $\pm$ 0.23	0.55 $\pm$ 0.10	9.4 $\pm$ 4.2	7.4 $\pm$ 1.9
7	1.51 $\pm$ 0.59	1.12 $\pm$ 0.36*	27.7 $\pm$ 16.3	21.9 $\pm$ 7.0
9	2.27 $\pm$ 0.92	1.37 $\pm$ 0.46***	50.7 $\pm$ 27.6	27.1 $\pm$ 9.7*
11	3.17 $\pm$ 1.00	2.65 $\pm$ 0.76	86.2 $\pm$ 38.9	59.6 $\pm$ 24.4
13	3.69 $\pm$ 0.56	3.37 $\pm$ 0.72	94.8 $\pm$ 22.0	87.4 $\pm$ 25.1
16	3.89 $\pm$ 0.17	3.80 $\pm$ 0.50	133.0 $\pm$ 40.7	146.0 $\pm$ 58.8

1 The 100 mg/kg/day dose was given by intraperitoneal injection on days 1, 3, 7 and 11 of the  
2 infection.

3 \*P<0.05, \*\*P<0.01, \*\*\*P<0.001

4 Conclusions

5 Treatment of vaccinia virus skin infections in immunosuppressed hairless mice with  
6 benzalkonium chloride two times a day for 3 or 6 days starting 24 hours after infection  
7 resulted in some benefit to the animals in terms of slightly longer survival times, and  
8 reductions in lesion scores and lesion areas. The effect of the compound was to delay disease  
9 progression, not to halt it entirely.

11 HYPOTHETICAL EXAMPLES

12 The following are hypothetical examples. These hypothetical examples include  
13 treatment compositions utilizing organochlorides other than benzalkonium chloride. More  
14 particularly, these organochlorides include: benzethonium chloride, methyl benzethonium  
15 chloride, cetyl pyridinium chloride, chloroxylonol, hexachlorophene, triclosan,  
16 chlorhexidine. Their chemical structures are also provided to show that a variety of  
17 organochlorides which differ structurally may be utilized. These organochlorides are also  
18 used at various concentrations. Additionally, different carriers are utilized.

20 EXAMPLE 1

21 In a first example, disordered tissue that has a redness of 10 of a nominal red scale  
22 is subjected to the inventive method by impregnating an applicator with about 0.02%  
23 benzalkonium chloride in isopropyl alcohol composition. The impregnated applicator is then  
24 vigorously applied to a labial disordered tissue for a time period of about 30 seconds. During  
25 the application time period, about 0.2 ml of the inventive composition is absorbed into the  
26 patient's disordered tissue. The patient's disordered tissue is estimated to have an area of  
27 about 0.5 cm<sup>2</sup>. The patient's disordered tissue is then examined and is found to have a



1 decreased nominal red scale to about 6 after about 24 hours and an increased eosinophil  
2 assay of about 40% before about one hour.

#### 3 4 COMPARATIVE EXAMPLE 1

5 In a first comparative example, an applicator with about 0.02% benzalkonium  
6 chloride in isopropyl alcohol is gently applied to a disordered tissue by dabbing such that  
7 substantially no pressure is applied sufficient to depress the tissue against hard tissue that lies  
8 underneath. The impregnated applicator is applied to a labial disordered tissue for a time  
9 period of about 30 seconds. During the application time period, about 0.1 ml of the inventive  
10 composition is absorbed into the patient's disordered tissue. The patient's disordered tissue  
11 is estimated to have an area of about 0.5 cm<sup>2</sup>. The patient's disordered tissue is then  
12 examined and is found to have a decreased nominal red scale from 10 to about 9 after about  
13 24 hours and an increased eosinophil assay of about 5% before about one hour.

#### 14 15 COMPARATIVE EXAMPLE 2

16 In another example comparative to the first example, a disordered tissue is treated  
17 substantially the same as in the first example with the exception that only isopropyl alcohol  
18 is impregnated in the applicator. The patient's disordered tissue is examined after the  
19 treatment and is found to have an unchanged nominal red scale score of 10 and a negligibly  
20 increased eosinophil assay. However, note that some reduction of redness occurs when just  
21 alcohol is used, especially when the disordered tissue is an open sore, as the alcohol tends  
22 to wash away toxic material. The redness returns as does the pain as toxins continue to  
23 build up since the source of the infection has not been eliminated. Note also that in the  
24 United States, alcohol cannot be listed as an active agent in the treatment of cold sores  
25 caused by herpes.

26

**EXAMPLE 2**

In a second example, all conditions are the same as in the first example with the following variations. An embodiment of the inventive composition is applied to a typical sterile bandage and left over the patient's disordered tissue for about one hour. The sterile bandage may double as part of the applicator. The composition contains, in addition to about 0.02% benzalkonium chloride in isopropyl alcohol, about 5% of a composition of lidocaine and prilocaine in about a 1:1 mixture. After the one hour time period, the patient's skin is substantially numbed, and the applicator is vigorously rubbed into the disordered tissue for about 30 seconds. The patient experiences significantly less pain than that experienced in the first example. The patient's disordered tissue is then examined and is found to have a decreased nominal red scale to about 3 from a beginning of eight after about 24 hours and an increased eosinophil assay of about 50% before about one hour.

**COMPARATIVE EXAMPLE 3**

In a second comparative example, all conditions are the same as in the second example except that no agitation of the disordered tissue occurs. The patient again experiences a numbing sensation after contact of the inventive composition with the cold sore, but is found to have a decreased nominal red scale to about nine and an increased eosinophil assay of about 10% before one hour.

**COMPARATIVE EXAMPLE 4**

In another example comparative to the second example, the applicator is impregnated with the lidocaine: prilocaine mixture in isopropyl alcohol but no benzalkonium chloride or any other active agent is included. The patient's disordered tissue is then examined and is found to have a nominal red scale of about nine and a negligibly increased eosinophil assay before one hour.

### EXAMPLE 3

In a third example, a patient with pink eye is administered the inventive composition containing about 0.01% benzalkonium chloride in a carrier that is substantially nonirritating to the sclera and supporting eye tissue. The patient, with washed and disinfected hands, then rubs the closed eyelid with the hand or fingers for about 30 seconds. The patient's eye is then examined and is found to have a decreased nominal red scale to about 1 after about 24 hours.

### COMPARATIVE EXAMPLE 5


In a third comparative example, a patient is treated exactly as in the third example except that no rubbing through the closed eyelid is carried out. The patient's eye is then examined and is found to have a decreased nominal red scale only to about 7 after about 24 hours.

### COMPARATIVE EXAMPLE 6

In another comparative example to the third example, the patient with pink eye is administered with a carrier but with no active agent therein. The patient's eye is then examined and is found to have a decreased nominal red scale to about 8 after about 24 hours.

### EXAMPLE 4


In this example, a treatment composition is formed with benzethonium chloride as the active agent. Hereinbelow is the chemical structure of benzethonium chloride:



The treatment composition is applied to disordered tissue like that in Example 1 which has a redness of 10 or a nominal red scale. The disordered tissue was on the patient's back. Note that when the treatment composition is applied to thicker sections of skin such as occur on the back it is more difficult to penetrate than on thinner sections such as the lip or cheek. Accordingly when treating such thick skin portions, it is necessary to increase the active agent concentration, rub and/or press harder, or agitate more frequently. The treatment composition includes about 0.01% benzethonium chloride in isopropyl alcohol. An applicator impregnated with the treatment composition is then vigorously applied to a labial disordered tissue for a time period of about 30 seconds. During the application time period, about 0.2 ml of the inventive composition is absorbed into the patient's disordered tissue. The patient's disordered tissue is estimated to have an area of about 0.5 cm<sup>2</sup>. The patient's disordered tissue is then examined after about one hour and is found to have reduced redness, which is however not as reduced compared to that achieved in Example 1. Similarly, the eosinophil assay is increased but not to the extent of that in Example 1 which used benzalkonium chloride.

### EXAMPLE 5


In this example, a treatment composition is formed with methyl benzethonium chloride as the active agent. Hereinbelow is the chemical structure of methyl benzethonium chloride:



The treatment composition is applied to disordered tissue like that in Example 1 which has a redness of 10 or a nominal red scale. The treatment composition includes about 0.02% methyl benzethonium chloride in a carrier comprising about 70% isopropyl alcohol by volume of the carrier and about 30% water. An applicator impregnated with the treatment composition is then vigorously applied to a labial disordered tissue for a time period of about 30 seconds. During the application time period, about 0.2 ml of the inventive composition is absorbed into the patient's disordered tissue. The patient's disordered tissue is estimated to have an area of about 0.5 cm<sup>2</sup>. The patient's disordered tissue is then examined after about one hour and is found to have reduced redness, which is however not as reduced compared to that achieved in Example 1. Similarly, the eosinophil assay is increased but not to the extent of that in Example 1 which used benzalkonium chloride.

#### EXAMPLE 6

In this example, a treatment composition is formed with cetyl pyridinium chloride as the active agent. Hereinbelow is the chemical structure of cetyl pyridinium chloride:




The treatment composition is applied to disordered tissue like that in Example 1 on a patient's arm which has a redness of 10 or a nominal red scale. The treatment composition includes about 2.0% cetyl pyridinium chloride in a carrier comprising about 60% isopropyl alcohol by volume of the carrier, about 30% water and 10% acetone. An applicator impregnated with the treatment composition is then vigorously applied to a labial disordered

tissue for a time period of about 30 seconds. During the application time period, about 0.2 ml of the inventive composition is absorbed into the patient's disordered tissue. The patient's disordered tissue is estimated to have an area of about 0.5 cm<sup>2</sup>. The patient's disordered tissue is then examined after about one hour and is found to have reduced redness, which is however not as reduced compared to that achieved in Example 1. Similarly, the eosinophil assay is increased but not to the extent of that in Example 1 which used benzalkonium chloride.

### EXAMPLE 7

In this example, a treatment composition is formed with chloroxylenol as the active agent. Hereinbelow is the chemical structure of chloroxylenol.




The treatment composition is applied to disordered tissue like that in Example 1 which has a redness of 10 or a nominal red scale. The treatment composition includes about 0.5% chloroxylenol in acetone. An applicator impregnated with the treatment composition is then vigorously applied to a labial disordered tissue for a time period of about 30 seconds. During the application time period, about 0.2 ml of the inventive composition is absorbed into the patient's disordered tissue. The patient's disordered tissue is estimated to have an area of about 0.5 cm<sup>2</sup>. The patient's disordered tissue is then examined after about one hour and is found to have reduced redness, which is however not as reduced compared to that

achieved in Example 1. Similarly, the eosinophil assay is increased but not to the extent of that in Example 1 which used benzalkonium chloride.

### EXAMPLE 8


In this example, a treatment composition is formed with hexachlorophene as the active agent. Hereinbelow is the chemical structure of hexachlorophene.



The treatment composition is applied to disordered tissue like that in Example 1 which has a redness of 10 or a nominal red scale. The treatment composition includes about 0.04% hexachlorophene in a carrier comprising about 80% isopropyl alcohol by volume of the carrier, about 15% water and 5% cetyl alcohol. An applicator impregnated with the treatment composition is then vigorously applied to a labial disordered tissue for a time period of about 30 seconds. During the application time period, about 0.2 ml of the inventive composition is absorbed into the patient's disordered tissue. The patient's disordered tissue is estimated to have an area of about 0.5 cm<sup>2</sup>. The patient's disordered tissue is then examined after about one hour and is found to have reduced redness, which is however not as reduced compared to that achieved in Example 1. Similarly, the eosinophil assay is increased but not to the extent of that in Example 1 which used benzalkonium chloride.

### EXAMPLE 9


In this example, a treatment composition is formed with triclosan as the active agent. Hereinbelow is the chemical structure of triclosan.



The treatment composition is applied to disordered tissue like that in Example 1 which has a redness of 10 or a nominal red scale. The treatment composition includes about 0.01% triclosan in a carrier comprising about 60% methyl alcohol by volume of the carrier, about 30% water and 10% acetone. An applicator impregnated with the treatment composition is then vigorously applied to a labial disordered tissue for a time period of about 30 seconds. During the application time period, about 0.2 ml of the inventive composition is absorbed into the patient's disordered tissue. The patient's disordered tissue is estimated to have an area of about 0.5 cm<sup>2</sup>. The patient's disordered tissue is then examined after about one hour and is found to have reduced redness, which is however not as reduced compared to that achieved in Example 1. Similarly, the eosinophil assay is increased but not to the extent of that in Example 1 which used benzalkonium chloride.

#### EXAMPLE 10

In this example, a treatment composition is formed with chlorhexidine as the active agent. Hereinbelow is the chemical structure of chlorhexidine.





The treatment composition is applied to disordered tissue like that in Example 1 which has a redness of 10 or a nominal red scale. The treatment composition includes about 0.03% chlorhexidine in methyl alcohol. An applicator impregnated with the treatment composition is then vigorously applied to a labial disordered tissue for a time period of about 30 seconds. During the application time period, about 0.2 ml of the inventive composition is absorbed into the patient's disordered tissue. The patient's disordered tissue is estimated to have an area of about 0.5 cm<sup>2</sup>. The patient's disordered tissue is then examined after about one hour and is found to have reduced redness, which is however not as reduced compared to that achieved in Example 1. Similarly, the eosinophil assay is increased but not to the extent of that in Example 1 which used benzalkonium chloride.

#### **EXAMPLE 11**

A treatment composition similar to the composition used in the Clinical Examples is applied to the smallpox lesions of a person suffering from smallpox. Based on the results set forth in the Clinical Examples, particularly those that showed an improvement when the composition was used to treat chicken pox, cold sores and shingles, it would be expected that the treatment composition would be effective in lessening the effects of smallpox, both in terms of the duration and extent of the small pox lesions as well as the ability to arrest the disease prior to death. The isopropyl alcohol carrier will break through and penetrate the cell walls of any infected cells and carry with it the benzalkonium chloride molecules, which will then kill the infected cells and prevent further advancement of the infection. The treatment composition will also act to breakdown any toxins released by the infected cells located in the skin area. It will also directly attack and denature any free viruses within the subcutaneous reservoir or bath of treatment composition. Based on the incubation period of smallpox virus, the treatment composition should be applied and then reapplied periodically until the disease is eradicated, such as 2-4 treatments a day for 1-3 weeks.

**EXAMPLE 12**

A treatment composition similar to the composition used in the Clinical Examples is applied to the skin of a person infected with anthrax. Based on the results set forth in the Clinical Examples, particularly those that showed an improvement when the composition was used to treat chicken pox, cold sores and shingles, as well as the knowledge that 70% isopropyl alcohol is effective in breaking through and penetrating cell walls, it would be expected that the treatment composition would be effective in lessening the effects of anthrax. The isopropyl alcohol carrier will break through and penetrate the anthrax bacteria's cell walls and carry with it the benzalkonium chloride molecules, which will then kill the anthrax cell and prevent further advancement of the infection. The treatment composition will also act to breakdown any toxins released by the anthrax cells located in the skin area. Based on the incubation period of the anthrax bacteria, the treatment composition should be applied and then reapplied periodically until the disease is eradicated, such as 2-4 treatments a day for 1-3 weeks.

The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrated and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

What is claimed and desired to be secured by United States Letters Patent is: